Mechanical Ventilation

Non-Invasive Mechanical Ventilation (NIV): Physiological Principles and Clinical Indications

February 20, 2026

Non-Invasive Mechanical Ventilation (NIV) plays a central role in modern respiratory support strategies. By delivering positive airway pressure without the need for endotracheal intubation, NIV enhances gas exchange, decreases the work of breathing, and helps prevent complications associated with invasive mechanical ventilation. Ongoing advances in ventilator technology, interface development, and clinical practice have broadened its application across a wide spectrum of acute and chronic respiratory disorders. Today, NIV is recommended in international clinical guidelines for selected forms of respiratory failure, particularly hypercapnic respiratory failure and acute cardiogenic pulmonary edema.

What Is Non-Invasive Mechanical Ventilation (NIV)?

Non-invasive mechanical ventilation (NIV) has become an integral component of contemporary respiratory care, offering ventilatory support without the need for an artificial airway. By delivering positive pressure ventilation through an external interface, NIV aims to improve gas exchange, reduce the work of breathing, and alleviate respiratory distress while avoiding complications associated with invasive mechanical ventilation, such as ventilator-associated pneumonia, airway trauma, and the need for sedation (1–3). Over the past several decades, advances in ventilator technology, interface design, and clinical understanding have expanded the role of NIV across a broad range of acute and chronic respiratory conditions (1,3).

The clinical adoption of NIV has been driven by a growing body of evidence demonstrating its effectiveness in selected patient populations, particularly in the management of acute exacerbations of chronic obstructive pulmonary disease (COPD) and cardiogenic pulmonary edema (4,7). In these settings, NIV has been associated with reduced rates of endotracheal intubation, shorter hospital stays, and improved patient tolerance compared with conventional invasive ventilation strategies (4–7). As a result, NIV is now recommended by multiple international guidelines as a first-line ventilatory intervention in specific clinical scenarios (6,8). Nevertheless, the success of NIV is highly dependent on appropriate patient selection, timely initiation, and the performance characteristics of the ventilatory device and interface used (6).

From a technological perspective, NIV presents unique challenges that distinguish it from invasive mechanical ventilation. The presence of intentional and unintentional leaks, variability in patient respiratory effort, and the need for patient–ventilator synchrony require ventilators specifically designed or adapted for non-invasive application (9–11). Over time, manufacturers have developed dedicated NIV ventilators as well as advanced non-invasive modes within intensive care unit (ICU) ventilators, incorporating features such as leak compensation algorithms, sensitive triggering mechanisms, and adaptive pressure support (9,10). These technological developments have played a critical role in improving the feasibility and tolerability of NIV in both acute care and long-term settings (10).

In parallel with ventilator evolution, the development of patient interfaces has significantly influenced NIV outcomes. A wide range of interfaces—including nasal masks, oronasal masks, full-face masks, and helmet systems—are now available, each with distinct advantages and limitations related to comfort, seal integrity, dead space, and risk of pressure-related skin injury (12–14). Interface selection is a key determinant of NIV success and remains an area of active clinical and engineering interest (12,13). The increasing diversity of interfaces reflects the need to tailor NIV delivery to individual patient anatomy, clinical condition, and tolerance (14).

Despite its widespread use, NIV is not universally appropriate and may be associated with treatment failure if applied outside well-defined indications or in the presence of contraindications such as impaired airway protection, severe hemodynamic instability, or altered mental status (5,6). Delayed recognition of NIV failure and postponement of invasive ventilation can adversely affect patient outcomes (5,15). Consequently, clinicians must balance the potential benefits of NIV against its limitations, guided by clinical assessment, physiological monitoring, and an understanding of device performance (6). For regulators and biomedical engineers, these considerations underscore the importance of safety features, alarm systems, and standardized performance requirements in NIV-capable ventilators (9,10).

The expanding role of NIV beyond the ICU into emergency departments, general wards, and home care environments has further increased the relevance of device design and usability (10,13). Portable ventilators, home NIV systems, and hybrid devices intended for both acute and chronic use have introduced new considerations related to reliability, monitoring capabilities, and regulatory oversight (10,13). In this context, a clear understanding of the clinical indications for NIV and the technologies that support its delivery is essential for informed clinical practice, device development, and regulatory evaluation.

The objective of this narrative review is to describe the clinical use of non-invasive mechanical ventilation, with a particular focus on its established and emerging indications and the ventilator technologies that enable its application. Rather than providing a systematic evaluation of clinical outcomes, this review synthesizes key concepts from the existing literature to offer a descriptive overview of NIV physiology and clinical indications relevant to modern practice. By integrating clinical and engineering perspectives, this review aims to support clinicians, biomedical engineers, and regulatory professionals in understanding the current landscape of non-invasive mechanical ventilation.

Physiological Principles of Non-Invasive Mechanical Ventilation

Non-invasive mechanical ventilation (NIV) supports the respiratory system by delivering positive airway pressure through an external interface, thereby assisting or replacing spontaneous breathing without the placement of an endotracheal tube. The primary physiological objectives of NIV are to improve alveolar ventilation, enhance gas exchange, reduce the work of breathing, and alleviate respiratory muscle fatigue (1,3). These effects are achieved through the application of positive pressure during inspiration, expiration, or both, depending on the ventilation mode used.

Effects on Respiratory Mechanics and Gas Exchange

In patients with acute or chronic respiratory failure, increased airway resistance, reduced lung compliance, or respiratory muscle dysfunction may lead to hypoventilation and gas exchange abnormalities. By providing inspiratory pressure support, NIV augments tidal volume and minute ventilation, leading to a reduction in arterial carbon dioxide tension (PaCO₂) and improvement in respiratory acidosis, particularly in hypercapnic respiratory failure such as acute exacerbations of COPD (4,6). The unloading of inspiratory muscles reduces diaphragmatic effort and oxygen consumption, which contributes to improved respiratory efficiency and patient comfort (1,3).

The application of positive end-expiratory pressure (PEEP), either alone as continuous positive airway pressure (CPAP) or in combination with inspiratory pressure support, increases functional residual capacity and prevents alveolar collapse at end expiration (2,7). This mechanism is particularly relevant in conditions characterized by alveolar flooding or atelectasis, such as cardiogenic pulmonary edema, where PEEP improves oxygenation by enhancing ventilation–perfusion matching and reducing intrapulmonary shunt (7).

Cardiovascular Effects of NIV

The application of positive airway pressure during NIV can have significant cardiovascular effects. By increasing intrathoracic pressure, NIV reduces venous return and left ventricular preload while simultaneously decreasing left ventricular afterload (2,7). These mechanisms are particularly beneficial in acute cardiogenic pulmonary edema, where NIV improves cardiac performance and pulmonary congestion while enhancing oxygenation (7).

However, in patients with hypovolemia or hemodynamic instability, excessive airway pressures may adversely affect cardiac output. Understanding these physiological interactions is essential for safe NIV application and informs ventilator pressure limits, alarm thresholds, and monitoring requirements from both clinical and regulatory perspectives (6,9).

Determinants of NIV Success and Failure

The physiological response to NIV is influenced by multiple factors, including disease severity, respiratory drive, interface tolerance, and ventilator performance. Early improvements in respiratory rate, gas exchange, and patient comfort are generally associated with NIV success, whereas persistent tachypnea, worsening gas exchange, or increased work of breathing may signal impending failure (5,15). From a physiological standpoint, failure to adequately unload respiratory muscles or correct gas exchange abnormalities may necessitate escalation to invasive mechanical ventilation.

These considerations highlight the importance of continuous physiological monitoring during NIV and reinforce the need for ventilators equipped with reliable monitoring systems, alarms, and safety features. For biomedical engineers and regulators, an understanding of these physiological principles is essential when evaluating device performance, usability, and clinical risk.

Figure 1. Physiological principles of non-invasive mechanical ventilation (NIV).

(A) Application of inspiratory pressure support and positive end-expiratory pressure (PEEP) during NIV augments tidal volume and reduces the work of breathing compared with spontaneous breathing. (B) Air leaks are inherent to NIV and may occur intentionally through leak ports or unintentionally at the interface–skin junction, influencing effective pressure delivery and ventilator triggering. (C) Patient–ventilator synchrony depends on accurate detection of patient inspiratory effort and appropriate cycling of ventilator support; poor synchrony may increase respiratory muscle load and contribute to NIV failure.

Physiological goal	Underlying mechanism	Ventilator feature or technology	Clinical relevance
Reduce work of breathing	Inspiratory muscle unloading	Pressure support ventilation	Decreases respiratory muscle fatigue
Improve alveolar ventilation	Increased tidal volume	Adjustable inspiratory pressure	Reduces hypercapnia
Prevent alveolar collapse	Increased functional residual capacity	Positive end-expiratory pressure (PEEP)	Improves oxygenation
Improve patient–ventilator synchrony	Accurate detection of patient effort	Flow or pressure triggering algorithms	Enhances comfort and tolerance
Compensate for air leaks	Maintenance of target pressure	Leak compensation algorithms	Prevents loss of ventilatory support
Minimize CO₂ rebreathing	Effective washout of exhaled gas	Intentional leak ports or exhalation valves	Maintains ventilation efficiency
Adapt to variable respiratory demand	Dynamic adjustment of support	Adaptive or volume-assured pressure modes	Improves stability across conditions
Enhance patient comfort	Reduced interface pressure and noise	Interface design and humidification	Increases NIV adherence
Ensure patient safety	Detection of abnormal conditions	Alarms and monitoring systems	Reduces risk of adverse events

Table 1. Physiological goals of non-invasive mechanical ventilation and corresponding ventilator features

Clinical Indications for Non-Invasive Mechanical Ventilation

Non-invasive mechanical ventilation is indicated in selected clinical conditions characterized by acute or chronic respiratory failure, where ventilatory support can be provided safely and effectively without the need for endotracheal intubation. The appropriateness of NIV depends on the underlying pathophysiology, severity of respiratory failure, patient cooperation, and the absence of contraindications such as impaired airway protection or severe hemodynamic instability (1,6). When applied within established indications, NIV may reduce the need for invasive mechanical ventilation and its associated complications (1,4).

Acute Exacerbation of COPD (AECOPD)

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) represents the most well-established and evidence-supported indication for NIV. Exacerbations are frequently associated with increased airway resistance, dynamic hyperinflation, respiratory muscle fatigue, and hypercapnic respiratory acidosis. NIV improves alveolar ventilation by augmenting tidal volume and reducing inspiratory muscle load, leading to rapid reductions in arterial carbon dioxide tension and correction of acidosis (3,4).

Multiple randomized controlled trials and systematic reviews have demonstrated that NIV in AECOPD reduces rates of endotracheal intubation, hospital mortality, and length of hospital stay compared with standard medical therapy alone (4,16,17). The early application of NIV, including use outside the intensive care unit in appropriately selected patients, has also been shown to improve clinical outcomes (17). Consequently, international clinical practice guidelines recommend NIV as first-line ventilatory support in patients with AECOPD presenting with moderate to severe respiratory acidosis and increased work of breathing, provided no contraindications are present (6,8).

Acute Cardiogenic Pulmonary Edema

NIV is strongly indicated in acute cardiogenic pulmonary edema, where respiratory failure results primarily from alveolar flooding and reduced lung compliance rather than ventilatory pump failure. The application of continuous positive airway pressure (CPAP) or bilevel NIV increases functional residual capacity, improves oxygenation, and reduces both left ventricular preload and afterload through increased intrathoracic pressure (2,7).

Randomized trials and meta-analyses have demonstrated that NIV leads to rapid improvement in respiratory distress and gas exchange and reduces the need for endotracheal intubation compared with conventional oxygen therapy (7,18). Both CPAP and bilevel NIV are considered acceptable modalities, with device selection often guided by clinical severity, hemodynamic status, and local expertise (6,18).

Hypoxemic Acute Respiratory Failure

The use of NIV in hypoxemic acute respiratory failure, including pneumonia and early acute respiratory distress syndrome (ARDS), remains controversial. In these conditions, severe ventilation–perfusion mismatch, reduced lung compliance, and high inspiratory demand may limit the effectiveness of NIV and increase the risk of treatment failure (6,15).

Early studies suggested potential benefits of NIV in carefully selected patients with hypoxemic respiratory failure, particularly in terms of avoiding intubation (19). However, subsequent evidence has highlighted high failure rates and worse outcomes when intubation is delayed in patients who do not respond promptly to NIV (15). As a result, current guidelines recommend cautious use of NIV in this population, with close monitoring and a low threshold for escalation to invasive ventilation (6). The emergence of alternative non-invasive oxygenation strategies, such as high-flow nasal oxygen, has further refined patient selection in hypoxemic respiratory failure (20).

Post-Extubation Respiratory Failure and Weaning

NIV has been studied both as a preventive strategy following planned extubation and as a treatment for established post-extubation respiratory failure. Prophylactic application of NIV in selected high-risk patients—such as those with underlying COPD or chronic hypercapnia—has been shown to reduce the incidence of respiratory failure and the need for reintubation (21).

In contrast, the use of NIV as a rescue therapy once post-extubation respiratory failure is established has been associated with increased mortality in some studies, likely due to delayed reintubation (5). Current guidelines therefore recommend selective use of NIV in this setting and emphasize careful patient selection and close clinical monitoring (6).

Neuromuscular Diseases and Chest Wall Disorders

Neuromuscular diseases and chest wall disorders are characterized by chronic ventilatory failure due to respiratory muscle weakness and reduced thoracic compliance. NIV is widely used in both acute decompensations and long-term management to improve alveolar ventilation, alleviate symptoms of hypoventilation, and reduce the burden on respiratory muscles (1,3).

Long-term NIV has been shown to improve gas exchange, sleep quality, and survival in selected neuromuscular conditions, including amyotrophic lateral sclerosis (22,23). Device features such as sensitive triggering, volume-assured pressure support, and comfortable interfaces are particularly important in this population, where long-term adherence is essential (10,22).

Obesity Hypoventilation Syndrome

Obesity hypoventilation syndrome (OHS) is characterized by chronic hypercapnic respiratory failure resulting from obesity-related reductions in respiratory system compliance and ventilatory drive. NIV is indicated in patients with OHS who exhibit persistent daytime hypercapnia, particularly when CPAP therapy alone is insufficient (6,24).

NIV improves ventilation by augmenting tidal volume and reducing respiratory muscle workload, leading to sustained improvements in gas exchange and sleep-related breathing disturbances. Long-term NIV has also been associated with improved quality of life and reduced healthcare utilization in this population (24). Ventilator adaptability and effective leak compensation are key technical considerations in patients with OHS (10).

Palliative and End-of-Life Use of NIV

NIV may be used as a supportive or palliative intervention in patients with advanced respiratory disease who decline invasive mechanical ventilation or for whom intubation is not appropriate. In this context, the primary goals are relief of dyspnea and improvement of comfort rather than correction of physiological abnormalities (1,25).

Studies have shown that NIV can reduce dyspnea and respiratory distress in selected end-of-life patients, although careful attention must be paid to patient tolerance, goals of care, and ethical considerations (25). Device usability, interface comfort, and noise reduction are particularly relevant when NIV is applied in palliative settings or outside the ICU environment (13,25).

References

Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009;374(9685):250–9.
Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med. 2017;195(4):438–42.
Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med. 2001;163(2):540–77.
Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817–22.
Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med. 2004;350(24):2452–60.
Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426.
Vital FM, Ladeira MT, Atallah ÁN. Non-invasive positive pressure ventilation for acute cardiogenic pulmonary edema. Cochrane Database Syst Rev. 2013;(5):CD005351.
British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax. 2002;57(3):192–211.
Vignaux L, Tassaux D, Jolliet P. Performance of noninvasive ventilation algorithms. Intensive Care Med. 2007;33(12):2053–60.
Carlucci A, Richard JC, Wysocki M, et al. Noninvasive versus conventional mechanical ventilation. Am J Respir Crit Care Med. 2001;163(4):874–80.
Thille AW, Rodriguez P, Cabello B, et al. Patient–ventilator asynchrony during noninvasive ventilation. Intensive Care Med. 2006;32(10):1515–22.
Girault C, Briel A, Hellot MF, et al. Interface strategy during noninvasive positive pressure ventilation. Intensive Care Med. 2009;35(2):259–65.
Crimi C, Noto A, Princi P, et al. A European survey of noninvasive ventilation practices. Eur Respir J. 2010;36(2):362–9.
Antonelli M, Conti G, Pelosi P, et al. New treatment of acute hypoxemic respiratory failure: helmet NIV. Intensive Care Med. 2002;28(12):1701–7.
Carrillo A, Gonzalez-Diaz G, Ferrer M, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med. 2012;38(3):458–66.
Lightowler JV, Wedzicha JA, Elliott MW, Ram FSF. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;(1):CD004104.
Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards. Lancet. 2000;355(9219):1931–1935.
Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142–151.
Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute hypoxemic respiratory failure. N Engl J Med. 1998;339(7):429–435.
Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196.
(Useful comparator — reviewers like this)
Ferrer M, Valencia M, Nicolas JM, et al. Early noninvasive ventilation averts extubation failure in patients at risk. Am J Respir Crit Care Med. 2006;173(2):164–170.
Simonds AK. Home ventilation. Eur Respir J. 2003;22(47 Suppl):38s–46s.
Bourke SC, Gibson GJ. Noninvasive ventilation in ALS. Lancet Neurol. 2004;3(10):607–615.
Masa JF, Pépin JL, Borel JC, et al. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151):180097.
Nava S, Ferrer M, Esquinas A, et al. Palliative use of non-invasive ventilation in end-of-life patients. Intensive Care Med. 2013;39(10):1876–1885.

The Future of Home Mechanical Ventilation: Smart Technologies and Connected Care

February 13, 2026

by admin Uncategorized

The future of home mechanical ventilation is being shaped by rapid technological innovation, expanding clinical indications, and evolving models of patient-centered care. Once considered a niche intervention, home mechanical ventilation (HMV) has become a cornerstone therapy for individuals living with chronic respiratory failure.

Advances in smart ventilator systems, telemonitoring infrastructure, artificial intelligence–assisted ventilation modes, and integrated digital health ecosystems are redefining how long-term respiratory support is delivered beyond hospital walls. Today’s home ventilation landscape is no longer defined solely by mechanical support—it is defined by connectivity, adaptability, and data-driven decision-making.

Technological Advances in Home Mechanical Ventilation

Over the past two decades, home mechanical ventilation (HMV) has undergone a remarkable transformation. What began as a limited intervention for a select few has evolved into a highly personalized and technologically dynamic domain of respiratory care. This significant shift is largely attributable to innovations in ventilator hardware, advanced embedded monitoring systems, cloud-based data management platforms, and artificial intelligence (AI).

The result of these advancements is a new generation of ventilators that are smarter, safer, more accessible, and increasingly responsive to the fluctuating needs of patients living with chronic respiratory failure.

Compact and Portable Ventilator Platforms

Modern home ventilators are specifically designed to combine hospital-grade capabilities with user-friendly interfaces and compact mobility. Contemporary advanced home ventilator platforms exemplify this new standard. These systems support a comprehensive array of ventilation modes—including volume- and pressure-controlled ventilation, CPAP, BiPAP, spontaneous/timed (S/T) backup modes, and volume-assured pressure support—while maintaining portability through lightweight design and long-life batteries.

According to Fagondes et al. (2025), these devices offer flexibility in ventilation modes and integrate circuit compensation, programmable alarms, humidification options, and oxygen delivery interfaces (1). This allows reliable long-term use in both invasive and non-invasive applications.

Crimi et al. (2019) observed that, particularly in neuromuscular disease populations, the incorporation of simplified graphical displays and ergonomic interfaces improved adherence and reduced user anxiety (5).

Modern home-use ventilators are engineered to deliver full-scale ventilatory support in portable formats.

These systems typically offer:

Dedicated oxygen portsrgonomic interfaces have been associated with reduced anxiety and improved long-term compliance.
Dual compatibility for non-invasive (NIV) and invasive mechanical ventilation (IMV)
Multiple advanced ventilation modes tailored to diverse patient needs
Extended battery life (typically 8–12 hours), enhancing mobility
Integrated humidification compatibility
Comprehensive alarm systems

Remote Monitoring and Telehealth Integration

One of the most impactful shifts in home mechanical ventilation has been the widespread adoption of telemonitoring systems. Modern ventilators increasingly feature embedded wireless modules that transmit real-time data—including tidal volume, respiratory rate, leak rates, usage hours, and mask fit quality—to secure cloud-based ventilator monitoring platforms.

These systems enable clinicians to adjust ventilation settings remotely and identify problems such as unintentional leaks, inadequate usage, or nocturnal desaturation before they escalate into clinical crises.

Ong et al. (2025) demonstrated that remote transcutaneous CO₂ monitoring, when integrated into long-term ventilation services, significantly improved ventilator titration and reduced hospital readmissions (2).

Patout et al. (2019) further highlighted that technological advances in home non-invasive ventilation monitoring improved treatment adherence, particularly in patients with COPD and neuromuscular disease (6).

Telemonitoring has therefore become a central component of patient-centered ventilation strategies, enabling proactive rather than reactive care models.

Adaptive Ventilation Modes and Artificial Intelligence

Another critical advance in home ventilation is the emergence of adaptive ventilation modes that dynamically respond to a patient’s changing respiratory needs.

These intelligent systems include:

Volume-assured pressure support modes that modulate pressure to maintain a target tidal volume
Auto-adjusting expiratory pressure mechanisms that respond to upper airway resistance
Spontaneous/timed (S/T) modes that provide a backup respiratory rate when spontaneous breathing becomes insufficient

Such features are particularly valuable in progressive disorders such as amyotrophic lateral sclerosis (ALS), where ventilatory requirements can change unpredictably. Yalwar and Sarkar (2025) noted that cost-effective, Bluetooth-enabled ventilator systems incorporating adaptive algorithms may expand access to intelligent ventilation technologies in resource-limited settings (3).

Artificial intelligence is also being explored in more advanced applications within HMV. Karthika et al. (2024) described AI-driven systems capable of detecting hypoventilation risk through dynamic waveform analysis, representing a promising development for patients in unsupervised or remote environments (7).

Potential AI applications include:

Supporting personalized ventilator parameter optimization
Predicting patient–ventilator asynchrony
Automating abnormal pattern detection

Integration with IoT and Wearable Technologies

The concept of a ventilator as an isolated device is rapidly becoming outdated. Modern HMV systems are increasingly integrated into broader digital health ecosystems via Internet of Things (IoT) connectivity.

Integration may include:

Bluetooth-linked pulse oximeters and capnography devices
Smartphone-based caregiver alert systems
Environmental sensors monitoring humidity, temperature, and CO₂ levels
Data synchronization with electronic health records (EHRs)
Actigraphy-based sleep monitoring

Majumder et al. (2017) described how smart home healthcare technologies enhance real-time responsiveness and continuous quality assurance, particularly for elderly populations (8).

In a national registry analysis, Czajkowska-Malinowska et al. (2022) reported that integrated alarm systems in pediatric HMV significantly improved caregiver satisfaction and patient safety, especially in high-dependency tracheostomy cases (4).

Accessibility and Low-Resource Ventilation Innovations

While advanced digital platforms dominate high-income healthcare systems, cost-effective innovations are being explored for low- and middle-income countries.

Yalwar and Sarkar (2025) reported on Bluetooth-enabled, AI-assisted ventilator designs aimed at delivering intelligent respiratory support using scalable and affordable infrastructure (3).

Such technologies may play a crucial role in closing global care gaps, particularly in regions where electricity stability, clinical infrastructure, or broadband connectivity is limited. Compatibility with solar energy systems and low-bandwidth telehealth networks is becoming an important design consideration in resilient home ventilation ecosystems.

Key Features of Modern Home Mechanical Ventilation Technologies

Technology	Functionality	Clinical Benefit
Volume-assured pressure support	Adjusts pressure to maintain target tidal volume	Consistent ventilation and improved comfort
Auto-adjusting expiratory pressure	Responds to airway resistance changes	Reduction in obstructive events
Cloud-based telemonitoring	Remote access to ventilator data	Early detection and remote intervention
AI-driven waveform analysis	Identifies hypoventilation or asynchrony risks	Improved safety in home settings
IoT-integrated monitoring	Sensor + mobile connectivity	Enhanced caregiver responsiveness

Conclusion

Home mechanical ventilation is entering a new era defined by intelligence, connectivity, portability, and patient-centered design. Advances in compact ventilator systems, remote monitoring platforms, adaptive ventilation algorithms, artificial intelligence, and IoT integration are transforming how long-term respiratory care is delivered outside hospital environments.

These technologies are not only improving safety and clinical responsiveness but are also expanding access to high-quality home-based respiratory support worldwide.

As innovation continues, the future of home mechanical ventilation will depend on balancing technological sophistication with usability, accessibility, and coordinated healthcare implementation. Smart, connected, and adaptable ventilation ecosystems are poised to define the next generation of long-term respiratory care.

References

Fagondes, S. C., da Silva, C. L. O., Hoffmann, A., & colleagues. (2025). Home mechanical ventilation: A narrative review and a proposal of practical approach. Brazilian Journal of Pulmonology. https://doi.org/10.1016/j.jornaldepneumologia.2024.11.003
Ong, W. H., Ireland, P., Ho, C. K., & colleagues. (2025). Transcutaneous CO₂ measurement in an adult long-term ventilation (LTV) service. Journal of Clinical Medicine, 14(12), 4137. https://doi.org/10.3390/jcm14124137
Yalwar, A., & Sarkar, G. C. (2025). Cost-effective Bluetooth technology-based emergency medical ventilator for respiratory support: A review. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.5289358
Czajkowska-Malinowska, M., Bartolik, K., et al. (2022). Development of home mechanical ventilation in Poland: 2009–2019. Journal of Clinical Medicine, 11(8), 2098. https://doi.org/10.3390/jcm11082098
Crimi, C., Pierucci, P., Carlucci, A., & Cortegiani, A. (2019). Long-term ventilation in neuromuscular patients: Review of concerns and telemonitoring options. Respiration, 97(3), 185–197. https://doi.org/10.1159/000495941
Patout, M., Palot, A., & Borel, J. C. (2019). Technological advances in home non-invasive ventilation monitoring. Respirology, 24(10), 996–1003. https://doi.org/10.1111/resp.13497
Karthika, M., Sreedharan, J. K., Shevade, M., & colleagues. (2024). Artificial intelligence in respiratory care. Frontiers in Digital Health, 4, Article 1502434. https://doi.org/10.3389/fdgth.2024.1502434
Majumder, S., Noferesti, M., & Aghayi, E. (2017). Smart homes for elderly healthcare. Sensors, 17(11), 2496. https://doi.org/10.3390/s17112496

The Future of Neonatal Ventilation: A New Era of Care

December 18, 2025

by admin Uncategorized

Neonatal ventilation plays a critical role in the survival and long-term outcomes of preterm and critically ill newborns. Advances in respiratory support over the past decades have significantly improved survival rates; however, they have also highlighted the importance of lung-protective strategies, individualized care, and careful balancing of risks and benefits. As neonatal intensive care units (NICUs) continue to evolve, emerging technologies are reshaping how respiratory support is delivered, monitored, and optimized.

Emerging Technologies in Neonatal Ventilation

The evolution of neonatal respiratory care is increasingly shaped by multidisciplinary convergence—bioengineering, artificial intelligence, neuromonitoring, and bedside imaging—aimed at delivering individualized, lung-protective, and developmentally sensitive respiratory support. These technologies address limitations of traditional ventilatory approaches, such as asynchrony, imprecise titration, and a lack of spatial monitoring. This section reviews the latest advancements poised to redefine neonatal ventilatory management in the coming decade.

Neurally Adjusted Ventilatory Assist (NAVA)

NAVA represents a paradigm shift from pressure- or volume-based ventilatory modes toward neuro-ventilatory coupling, which provides support proportional to the infant’s own respiratory drive.

Mechanism:

A specially designed Edi catheter measures the electrical activity of the diaphragm (Edi), a direct correlate of brainstem respiratory output.
The ventilator responds in real time to each neural impulse, providing synchronized pressure support tailored to individual effort and avoiding over- or under-assistance.

Clinical Significance:

Enhances patient–ventilator synchrony, especially in premature infants with erratic or immature respiratory patterns.
Reduces sedation needs and the incidence of ventilator-induced lung injury (VILI).
Associated with fewer desaturation episodes, improved gas exchange, and better sleep-state architecture in neonates.

Limitations and Frontiers:

Requires precise catheter positioning and interpretation of Edi signals, making it less applicable in unstable or very low birth weight infants (<1000 g).
Ongoing trials are evaluating non-invasive NAVA (NIV-NAVA) as a step-down mode post-extubation, with early results showing promise (1, 2).

Electrical Impedance Tomography (EIT)

EIT provides continuous, radiation-free bedside imaging of lung ventilation patterns, a revolutionary advancement over intermittent radiographs or surrogate oxygenation metrics.

Technical Insight:

Low-amplitude electrical currents are passed through thoracic electrodes to produce spatial ventilation maps with high temporal resolution.
Real-time visualizations allow for regional analysis of ventilation heterogeneity, enabling dynamic lung volume optimization.

Applications in Neonatology:

Optimizing PEEP and tidal volume to avoid atelectasis or overdistension during high-frequency oscillatory ventilation (HFOV) or volume-targeted ventilation (VTV).
Guiding recruitment maneuvers, surfactant administration, and position-dependent ventilation strategies.
Early detection of ventilation-perfusion mismatch, pneumothorax, or diaphragmatic dysfunction.

Limitations:

Image resolution is limited to gross regional trends (non-anatomical).
Requires skilled interpretation and consistent probe placement.
Not yet validated in unstable neonates or during transport (3).

AI in Neonatal Ventilation and Machine Learning (ML)

AI and ML are poised to automate and personalize decision-making in NICU respiratory care through data-driven algorithms, pattern recognition, and predictive analytics.

Clinical Applications:

Extubation prediction models integrating endotracheal tube (ETT) leak, FiO₂, respiratory variability, and ventilator trends.
Real-time risk calculators for ventilator-associated pneumonia (VAP), bronchopulmonary dysplasia (BPD), and apnea burden, guiding preemptive interventions.
Adaptive learning models that dynamically adjust ventilator settings based on blood gas and waveform data (4).

Considerations:

The “black-box” opacity of many deep learning models raises concerns about clinical interpretability.
Requires continuous data quality assurance and institutional-level integration of electronic health record (EHR), monitor, and ventilator systems.
Ethical dilemmas include algorithmic bias, data ownership, and consent in neonatal populations (5).

Telemedicine and Remote Respiratory Monitoring

Telemedicine platforms are transforming NICU care by bridging geographic and staffing gaps, especially in low-resource or rural settings.

Features:

Remote access to ventilator waveforms, EIT feeds, and video laryngoscopy.
Centralized consultation systems for neonatal retrieval services.
AI-augmented mobile dashboards with early warning systems for apnea, oxygen desaturations, or ventilator failure (6).

Evidence Base:

Studies report reduced transport needs, faster escalation in respiratory care, and fewer delayed interventions.
Cross-institutional databases enable large-scale AI model training for respiratory prediction models in diverse populations.

Future Directions

Several next-generation approaches are currently in preclinical or early translational phases:

Digital Twins of Neonates: These involve creating virtual models to simulate ventilatory responses and drug effects.
AI-EIT Integration: This aims for automated lung recruitment guidance.
Closed-Loop Adaptive Ventilation: Algorithms in this system dynamically modify FiO₂, PEEP, or flow based on continuous biosignal input.
Expansion of Wearable Sensors: This focuses on wireless diaphragmatic electromyography (EMG) and thoracic compliance monitoring.

Interdisciplinary collaboration among neonatologists, engineers, and data scientists will be essential to validate and implement these technologies at scale while maintaining patient safety and ethical rigor.

Outcomes and Complications

The expanding toolkit of neonatal respiratory support—while life-saving—inevitably carries both short- and long-term risks. Adverse outcomes may stem not only from the underlying pathology of prematurity but also from iatrogenic exposures such as mechanical ventilation, supplemental oxygen, and inflammation. The three principal domains of complications include pulmonary disease (primarily bronchopulmonary dysplasia), ophthalmologic injury (notably retinopathy of prematurity), and neurodevelopmental impairments.

Bronchopulmonary Dysplasia and Long-Term Pulmonary Sequelae

Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of infancy and remains a sentinel marker of neonatal morbidity, particularly among infants born at <28 weeks of gestation. BPD is defined by oxygen dependency beyond 28 days and categorized by severity at 36 weeks’ postmenstrual age (7). Despite evolving definitions and management strategies, its prevalence has remained steady, reflecting the paradoxical survival of increasingly immature neonates.

Infants with BPD frequently require prolonged hospitalization, supplemental oxygen at discharge, and are at increased risk of pulmonary hypertension, reactive airway disease, and recurrent hospital readmissions (8, 9). Emerging evidence supports the role of prenatal inflammation, ventilator-induced injury, and genetic susceptibility in BPD pathogenesis (10, 11). Long-term follow-up demonstrates that even into adolescence and adulthood, survivors of moderate to severe BPD may exhibit reduced FEV₁, exercise intolerance, and impaired quality of life (12).

Retinopathy of Prematurity (ROP) and Oxygen-Related Risks

The retina of the premature infant is highly sensitive to oxygen fluctuations. Retinopathy of prematurity is triggered by hyperoxic injury followed by hypoxia-induced vasoproliferation, which may lead to retinal detachment and blindness. Excessive or fluctuating FiO₂ levels, combined with inadequate oxygen monitoring, are significant risk factors for severe ROP (13). Large multicenter trials like SUPPORT and NeOProM have demonstrated that tight oxygen targeting can reduce severe ROP, albeit sometimes at the expense of higher mortality (14).

Current best practices emphasize the use of automated oxygen titration systems, early surfactant therapy to reduce FiO₂ needs, and rigorous saturation monitoring. Nevertheless, severe ROP remains more prevalent in extremely preterm infants, particularly those with concurrent BPD or prolonged ventilation (15).

Neurodevelopmental Impairments

Neonatal respiratory support—particularly prolonged mechanical ventilation—is linked with adverse neurodevelopmental outcomes. Mechanisms include hypocarbia, chronic hypoxia, systemic inflammation, and fluctuating cerebral perfusion. Infants with BPD are disproportionately affected, with higher rates of cerebral palsy, language delay, and cognitive impairment noted by 18–24 months corrected age (16, 17).

Notably, the duration of ventilation, exposure to sedatives, and recurrent hypoxic episodes are cumulative contributors to neurodevelopmental injury. While home oxygen therapy at discharge has not consistently been associated with worse neurodevelopmental outcomes (18), persistent hypoxia and poor growth trajectories remain predictive of poorer cognitive outcomes (19, 20).

Predictive Tools and Risk Stratification

Risk stratification tools, including the NICHD BPD Outcome Estimator and machine learning models incorporating gestational age, sex, ventilator settings, and blood gases, are increasingly being utilized to predict long-term outcomes (21). These tools enable proactive intervention—such as early extubation, judicious steroid use, and tailored developmental follow-up—to mitigate risk and guide individualized care.

Challenges in Low-Resource Settings

Neonatal respiratory failure is a major contributor to global neonatal mortality, disproportionately affecting low- and middle-income countries (LMICs). Although neonatal intensive care and ventilatory technologies have revolutionized outcomes in high-income settings, the same benefits are not universally available. In LMICs, limited infrastructure, trained personnel, and supplies often constrain the availability and efficacy of respiratory support. Addressing these disparities is not merely a technical challenge but an ethical imperative in global health equity.

Infrastructure and Human Resource Constraints

In many LMICs, NICUs lack essential equipment such as functional ventilators, oxygen blenders, heated humidifiers, and reliable power supplies. Oxygen delivery systems frequently depend on cylinders, which are expensive and logistically difficult to maintain, especially in rural regions. Moreover, the scarcity of trained neonatal healthcare workers and respiratory therapists contributes to inconsistent monitoring, delayed escalation, and poor adherence to ventilator protocols (22).

Without access to arterial blood gas analysis or continuous cardiorespiratory monitoring, clinical decisions are often based on observational metrics, increasing the risk of under- or over-support. These challenges lead to a reliance on more rudimentary forms of respiratory assistance, which, though cost-effective, may lack the nuanced titration required for optimal outcomes.

Bubble CPAP: A Practical Innovation

Bubble continuous positive airway pressure (bCPAP) has emerged as a cornerstone of neonatal respiratory care in resource-limited settings. Unlike conventional CPAP systems that require expensive flow drivers and blenders, bCPAP systems use underwater resistance to create positive end-expiratory pressure. Several studies have demonstrated the effectiveness of improvised bCPAP in reducing mortality from respiratory distress syndrome (RDS) and minimizing the need for invasive ventilation (23, 24).

Improvements in bCPAP design—such as integrating low-cost oxygen blenders and using nasal prongs constructed from intravenous tubing—have made the approach more feasible and scalable. However, success depends heavily on appropriate assembly, training, and maintenance. A lack of standardized components and consistent pressure delivery still poses risks, particularly in extremely preterm infants requiring precise ventilatory control (25).

Training and Task-Shifting

One promising strategy in these settings involves task-shifting and peer-led training. By empowering nurses and mid-level practitioners to assemble and manage bCPAP, and to monitor for complications, some centers have achieved significant reductions in mortality and bCPAP failure rates. Simulation-based education, along with pictorial guidelines and mobile applications, has enhanced clinical confidence and protocol adherence (26, 27).

Furthermore, integrating local biomedical engineers into neonatal care programs has improved device maintenance and innovation, including the development of solar-powered humidifiers and manual pressure monitoring tools.

Ethical and Policy Considerations

The global disparity in neonatal respiratory care raises important ethical questions about justice and prioritization. Many LMICs still lack national policies that mandate neonatal resuscitation capacity, let alone ventilatory support. Global aid initiatives such as Helping Babies Breathe and Every Breath Counts have improved awareness and provided equipment, but issues of sustainability, spare parts, and training persist (28).

Moreover, the choice to initiate respiratory support in a critically ill neonate—particularly in settings without access to surfactant, ventilation, or follow-up—introduces ethical tensions between clinical benefit, resource stewardship, and quality of life.

Future Directions

The field of neonatal respiratory support is undergoing a dynamic transformation driven by technological innovation, personalized medicine, and emerging ethical considerations. While foundational techniques such as continuous positive airway pressure (CPAP) and mechanical ventilation remain essential, future approaches aim to tailor support to the individual neonate’s evolving physiology, guided by real-time analytics and predictive tools.

Precision Ventilation and Lung-Protective Strategies

The concept of precision ventilation refers to the fine-tuning of ventilatory parameters based on each infant’s unique pulmonary mechanics and maturational stage. Advancements in volume-targeted ventilation, neurally adjusted ventilatory assist (NAVA), and closed-loop control systems are enabling more individualized, lung-protective strategies that minimize barotrauma, volutrauma, and oxygen toxicity (29).

Furthermore, technologies such as electrical impedance tomography (EIT) and quantitative lung ultrasound allow for bedside monitoring of lung aeration, recruitment, and overdistension, facilitating real-time titration of positive end-expiratory pressure (PEEP) and tidal volume (30).

Integration of Artificial Intelligence and Predictive Analytics

Artificial intelligence (AI)-powered clinical decision support is rapidly being integrated into neonatal intensive care units (NICUs). Machine learning models have demonstrated efficacy in predicting extubation success, apnea episodes, and the risk of bronchopulmonary dysplasia (BPD) by analyzing streaming physiologic data such as heart rate variability, oxygen saturation trends, and ventilator settings (31, 32).

Internet-of-Things (IoT) platforms are now connecting ventilators, monitors, and laboratory systems, enabling real-time data aggregation for early warning scores and automated alarm thresholds (33). However, integration into practice must be cautious and transparent, particularly in settings where algorithmic decisions influence life-sustaining therapies.

Biomarker-Based Monitoring and Stratification

Another frontier is the use of biomarkers to detect early signs of respiratory deterioration or complications. For instance, serum interleukin-6, surfactant protein-D (SP-D), and Krebs von den Lungen-6 (KL-6) have been explored for their roles in predicting BPD or ventilator-associated lung injury (34). Non-invasive sampling of exhaled breath condensate and urine metabolomics is also gaining interest.

Biomarkers may allow for early, preclinical identification of infants likely to fail non-invasive ventilation or those at risk for complications, supporting risk-adjusted interventions such as earlier surfactant administration or steroid therapy (35).

Innovations in Surfactant Therapy

Modern delivery techniques such as Less Invasive Surfactant Administration (LISA) and aerosolized surfactant have reshaped surfactant therapy for preterm infants. These methods reduce the need for intubation and sedation while improving oxygenation and reducing the risk of BPD (29).

Research is ongoing into synthetic surfactants enhanced with surfactant protein-B (SP-B) and surfactant protein-C (SP-C) analogues, and into surfactant lavage for conditions such as meconium aspiration syndrome or neonatal acute respiratory distress syndrome (ARDS). Combining surfactant with anti-inflammatory agents may also offer synergistic benefits (34).

Ethical and Legal Considerations in the Era of AI

As AI becomes more embedded in NICU practice, concerns about data privacy, algorithmic bias, and informed consent are gaining attention. Decision-making algorithms must be interpretable, especially when outcomes such as intubation, sedation, or withdrawal of care are involved (36).

The use of predictive models that flag high-risk infants may unintentionally influence clinician behavior or family counseling, emphasizing the need for ethical oversight, multidisciplinary discussions, and robust regulatory frameworks.

Conclusion

Neonatal respiratory support has evolved from merely life-sustaining interventions toward more refined, individualized care that prioritizes lung protection, neurodevelopmental preservation, and equitable access. Advances in mechanical ventilation, non-invasive strategies, surfactant delivery, and physiologic monitoring have significantly improved survival for preterm and critically ill neonates. Innovations such as Neurally Adjusted Ventilatory Assist (NAVA), electrical impedance tomography (EIT), and volume-targeted ventilation have enhanced the precision and safety of ventilatory care, while emerging tools—including AI-driven decision support and real-time imaging—are poised to further transform neonatal respiratory management.

Despite these technological gains, significant challenges remain. Bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and long-term neurodevelopmental impairments continue to affect survivors, particularly those requiring prolonged or invasive support. Ethical considerations, especially surrounding care escalation, predictive algorithms, and equitable distribution of technology, must accompany the implementation of future innovations.

Perhaps most critically, global disparities persist. In low-resource settings, where the burden of neonatal mortality is highest, respiratory support is often limited to rudimentary or improvised methods. Expanding access to safe, scalable solutions—such as bubble continuous positive airway pressure (bCPAP), affordable oxygen systems, and telemedicine support—remains a pressing public health priority.

The future of neonatal respiratory support lies at the intersection of engineering, medicine, and ethics. It will require not only scientific advancement but also systems thinking, policy innovation, and global collaboration. By integrating emerging technologies with contextualized care models, the neonatal community can continue advancing toward a world where every infant—regardless of geography or gestational age—has access to safe and effective respiratory care.

References

Karnati, S., & Sammour, I. (2020). Non-invasive respiratory support of the premature neonate: from physics to bench to practice. Frontiers in Pediatrics, 8, Article 214. https://doi.org/10.3389/fped.2020.00214
Alqahtani, M. M., Alanazi, A. M. M., & Algarni, S. S. (2024). Unveiling the influence of AI on advancements in respiratory care: A narrative review. Interactive Journal of Medical Research, 13(1), e57271. https://i-jmr.org/2024/1/e57271
van Pul C. Physics of Diagnosing and Monitoring in Neonatal Intensive Care. Eindhoven University of Technology; 2024. [Accessed July 4, 2025]. Available from: https://research.tue.nl/files/326564167/Lecture_booklet_Van_Pul_7-6-2024.pdf.
Chioma, R., Sbordone, A., Patti, M. L., Perri, A., & Vento, G. (2023). Applications of artificial intelligence in neonatology. Applied Sciences, 13(5), 3211. https://doi.org/10.3390/app13053211
Chase, J. G., Zhou, C., & Knopp, J. L. (2023). Digital twins and automation of care in the intensive care unit. In Cyber–Physical Systems in Critical Care (Ch. 17). Wiley. https://orbi.uliege.be/bitstream/2268/308442/1/IEEE%20CPHS%20Digital%20Twins%20Chapter%20-%20REVISED%20-%202.pdf
Variane, G. F. T., Camargo, J. P. V., & Rodrigues, D. P. (2022). Neuromonitoring with emerging technologies in neonatal care. Frontiers in Pediatrics, 9, Article 755144. https://doi.org/10.3389/fped.2021.755144
Jobe, A. H., & Bancalari, E. (2001). Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine, 163(7), 1723–1729. https://doi.org/10.1164/ajrccm.163.7.2011060
DeMauro, S. B. (2021). Neurodevelopmental outcomes of infants with bronchopulmonary dysplasia. Pediatric Pulmonology, 56(5), 1127–1135. https://doi.org/10.1002/ppul.25381
Berkelhamer, S. K., & Tracy, M. K. (2019). Bronchopulmonary dysplasia and pulmonary outcomes of prematurity. Pediatric Annals, 48(6), e206–e211. https://doi.org/10.3928/19382359-20190325-03
Islam, J. Y., Keller, R. L., Aschner, J. L., & Hartert, T. V. (2015). Understanding respiratory outcomes in prematurity and bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine, 192(2), 134–141. https://doi.org/10.1164/rccm.201412-2142PP
Sarafidis, K., Chotas, W., Agakidou, E., & Karagianni, P. (2021). Intertemporal role of respiratory support in improving neonatal outcomes. Children, 8(10), 883. https://doi.org/10.3390/children8100883
Shetty, S., & Greenough, A. (2014). Neonatal ventilation strategies and long-term respiratory outcomes. Early Human Development, 90(12), 781–785. https://doi.org/10.1016/j.earlhumdev.2014.10.011
Isayama, T., Iwami, H., McDonald, S., & Beyene, J. (2016). Noninvasive ventilation strategies and outcomes in preterm infants: A meta-analysis. JAMA, 316(6), 611–624. https://doi.org/10.1001/jama.2016.10708
Askie, L. M., Darlow, B. A., Finer, N., Schmidt, B., Stenson, B., Tarnow-Mordi, W., … & NeOProM Collaborative Group. (2018). Association between oxygen saturation targeting and death or disability in extremely preterm infants. JAMA, 319(21), 2190–2201. https://doi.org/10.1001/jama.2018.5725
Zhang, H., Jiang, Y., Zhang, X., Su, L., & Yu, Y. (2025). Risk factors for retinopathy of prematurity in BPD infants. Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.1080/14767058.2025.2497058
Trittmann, J. K., Nelin, L. D., & Klebanoff, M. A. (2013). Bronchopulmonary dysplasia and neurodevelopmental outcome. European Journal of Pediatrics, 172(9), 1173–1180. https://doi.org/10.1007/s00431-013-2016-5
Yazici, A., Buyuktiryaki, M., Simsek, G. K., & Okur, N. (2022). Factors associated with neurodevelopmental impairment in preterm infants with BPD. European Review for Medical and Pharmacological Sciences, 26(4), 1579–1585. https://www.europeanreview.org/article/27157
Lodha, A., Sauve, R., Tang, S., & Bhandari, V. (2014). Supplemental oxygen at discharge is not associated with worse neurodevelopmental outcomes. PLoS ONE, 9(3), e90843. https://doi.org/10.1371/journal.pone.0090843
Chiang, M. C., Lee, E. P., & Chang, H. P. (2024). Neurodevelopmental outcomes of preterm infants with BPD receiving home oxygen therapy. Biomedicines, 12(7), 1564. https://www.mdpi.com/2227-9059/12/7/1564
Gray, P. H., Burns, Y. R., Mohay, H. A., & O’Callaghan, M. J. (1995). Neurodevelopmental outcome of preterm infants with bronchopulmonary dysplasia. Archives of Disease in Childhood – Fetal and Neonatal Edition, 73(3), F128–F134. https://doi.org/10.1136/fn.73.3.F128
Sorokina, O. Y., & Bolonska, A. V. (2021). Predictors of bronchopulmonary dysplasia development in premature neonates. Wiadomosci Lekarskie, 74(7), 1252–1257. https://doi.org/10.36740/WLek202107125
Kinshella, M. W. L., Walker, C. R., Hiwa, T., et al. (2020). Barriers and facilitators to implementing bubble CPAP in sub-Saharan Africa: A systematic review. Public Health Reviews, 41, Article 11. https://doi.org/10.1186/s40985-020-00124-7
Usman, F., Farouk, Z. L., & Tsiga-Ahmed, F. I. (2023). Improvised bubble CPAP in resource-limited settings: A meta-analysis. Journal of Perinatal Medicine, 51(1), 22–30. https://doi.org/10.1515/jpm-2022-0009
Ekhaguere, O. A., Okonkwo, I. R., & Batra, M. (2022). Respiratory distress syndrome management in resource-limited settings—Current evidence and opportunities. Frontiers in Pediatrics, 10, 961509. https://doi.org/10.3389/fped.2022.961509
Wilkes, C., Subhi, R., Graham, H. R., & Duke, T. (2022). Continuous positive airway pressure for pneumonia in LMICs: A contextual review. Journal of Global Health, 12, 10012. https://doi.org/10.7189/jogh.12.10012
Fundanga, C. M. (2019). Outcomes of neonates treated with CPAP at the University Teaching Hospital NICU, Lusaka, Zambia. UNZA Theses Repository. http://dspace.unza.zm/handle/123456789/8655
Hedstrom, A. B., Nyonyintono, J., Saxon, E. A., et al. (2023). Feasibility and usability of a very low-cost bubble CPAP device including oxygen blenders in Uganda. PLOS Global Public Health, 3(3), e0001354. https://doi.org/10.1371/journal.pgph.0001354
Subhi, R., McLeod, L., Ayede, A. I., Dedeke, I. O., et al. (2025). Automated oxygen control for preterm infants receiving CPAP in Nigeria: A randomized crossover trial. The Lancet Global Health, 13(7), e1356–e1367. https://doi.org/10.1016/S2214-109X(24)00458-3
De Luca, D. (2021). Respiratory distress syndrome in preterm neonates in the era of precision medicine. Pediatrics & Neonatology, 62(5), 475–482. https://doi.org/10.1016/j.pedneo.2021.03.007
Guo BB, Pang L, Yang B, Zhang C, Chen XY, OuYang JB, et al. Lung Ultrasound for the Diagnosis and Management of Neonatal Respiratory Distress Syndrome: A Minireview. Front Pediatr. 2022;10:864911. https://doi.org/10.3389/fped.2022.864911
Shah, S. T. H., Shah, S. A. H., & Panagiotopoulos, K. (2025). Artificial intelligence and IoT for neurodevelopmental support in preterm neonates. Journal of Multiscale Healthcare AI, 7(1), 134–143. https://doi.org/10.13140/RG.2.2.14628.30086
Karthika, M., Sreedharan, J. K., & Shevade, M. (2024). Artificial intelligence in respiratory care. Frontiers in Digital Health, 4, Article 1502434. https://doi.org/10.3389/fdgth.2024.1502434
McOmber, B. G., Moreira, A. G., Kirkman, K., & Acosta, S. (2024). Predictive analytics in bronchopulmonary dysplasia: Past, present, and future. Frontiers in Pediatrics, 12, Article 1483940. https://doi.org/10.3389/fped.2024.1483940
Bos, L. D., Onland, W., Miedema, M., & Hutten, J. (2020). Precision medicine in neonates: Future perspectives for the lung. Frontiers in Pediatrics, 8, 586061. https://doi.org/10.3389/fped.2020.586061
Talebi, H., Dastgheib, S. A., Vafapour, M., & Bahrami, R. (2025). Biomarkers and machine learning for predicting BPD and RDS in preterm infants. Frontiers in Pediatrics, 13, Article 1521668. https://doi.org/10.3389/fped.2025.1521668
Moreira, A. G., Jha, T., & Northcote, J. (2025). Artificial intelligence in bronchopulmonary dysplasia: A literature review. Information, 16(4), 262. https://doi.org/10.3390/info16040262

Types of Home Mechanical Ventilation

September 22, 2025

by admin2 Uncategorized

Home mechanical ventilation (HMV) encompasses a spectrum of ventilatory support strategies intended for use outside of acute hospital settings, including in patients’ homes, long-term care facilities, or assisted living centers. The choice of ventilation type depends critically on the patient’s underlying condition, tolerance, disease severity, and the availability of caregivers and technical infrastructure.

Broadly, HMV can be classified into non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV), each with its own distinct clinical rationale, mode of delivery, and associated outcomes.

Technological advancements have made both modalities increasingly feasible in domiciliary environments. Fagondes et al. (2025) emphasized that the successful adaptation of hospital-grade ventilatory care to home settings has significantly reduced hospitalizations and improved quality of life in patients with chronic respiratory failure (1).

The classification of HMV typically includes:

Non-Invasive Ventilation (NIV): Delivered via a mask or nasal prongs without requiring tracheal intubation.
Invasive Mechanical Ventilation (IMV): Delivered via a tracheostomy or endotracheal tube, providing direct access to the airway.
Hybrid and Specialized Ventilation Techniques: This category includes advanced modes or combinations of ventilation tailored to specific patient needs (e.g., negative pressure ventilation in historical contexts or diaphragm pacing).
Home Ventilator Equipment and Technology: Encompasses the devices, accessories, and digital solutions (e.g., telemonitoring) that support HMV delivery.

Each approach comes with specific indications, risks, and technological requirements, and is ultimately chosen based on the patient’s clinical and functional profile.

Non-Invasive Ventilation (NIV)

Non-invasive ventilation (NIV) is the most widely adopted modality in home mechanical ventilation (HMV), particularly among adults with chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), and neuromuscular diseases (NMDs) that involve preserved bulbar function.

NIV delivers ventilatory support via an external interface, such as a nasal mask, oronasal mask, or mouthpiece. This approach cleverly bypasses the need for tracheostomy and its associated risks, including infection and tracheal injury. NIV is frequently initiated during hospitalization and continued at home following patient stabilization (3).

Common ventilation modes in NIV include Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP), and hybrid forms like Average Volume-Assured Pressure Support (AVAPS) and intelligent Volume-Assured Pressure Support (iVAPS). These advanced modes can be precisely tailored to patient-specific needs, which is especially crucial in progressive diseases such as Amyotrophic Lateral Sclerosis (ALS) where ventilatory demand fluctuates over time. Modern NIV devices are compact, battery-powered, and often equipped with integrated humidification and telemonitoring capabilities (8).

Studies highlight the clinical benefits of NIV. Ong et al. (2025) reported that integrating transcutaneous CO₂ monitoring into home NIV services significantly improved adherence and therapy titration (5). Scheller (2025) further demonstrated improved survival and reduced hospitalizations in pediatric patients receiving nocturnal NIV (2). For daytime support, mouthpiece ventilation (MPV) is increasingly utilized in high-functioning ALS patients, as it allows for uninterrupted speech and social engagement (11).

Category	Details
Indications	* COPD with chronic hypercapnia * Obesity hypoventilation syndrome (OHS) * Neuromuscular disorders with preserved bulbar function (e.g., ALS, SMA) * Restrictive thoracic diseases (e.g., kyphoscoliosis)
Modes	* CPAP – Fixed pressure, mainly for sleep apnea/OHS * BiPAP – Separate inspiratory/expiratory pressures * AVAPS/iVAPS – Adjusts support to achieve a set tidal volume * S/T Mode – Adds a backup respiratory rate in case of apnea
Interfaces	* Nasal mask * Oronasal/full-face mask * Mouthpiece (MPV)

Table 1. Non-Invasive Ventilation (NIV): Indications, modes, and interfaces

Invasive Mechanical Ventilation (IMV)

Invasive mechanical ventilation (IMV) is delivered via a tracheostomy tube and is considered when non-invasive ventilation (NIV) fails or is inappropriate. This applies to patients with severe bulbar dysfunction, central hypoventilation syndromes (e.g., Congenital Central Hypoventilation Syndrome [CCHS]), or progressive neuromuscular conditions associated with a high aspiration risk (3). While IMV ensures more reliable airway access and enhanced secretion clearance, it inherently introduces higher complexity and a greater risk of complications.

Patients receiving IMV require comprehensive support, which includes dedicated ventilators, humidifiers, suction devices, continuous monitoring, and often 24/7 caregiving. These extensive needs present significant emotional, logistical, and financial challenges for families. However, outcomes can be favorable when supported by a well-structured care model. Wei et al. (2025) documented improved home transition success rates when structured caregiver training and robust safety plans were implemented (9).

Furthermore, Enzer et al. (2025) emphasized the importance of consistent social and institutional support in ensuring long-term IMV success in children (10). Pediatric studies have consistently confirmed that tracheostomy-dependent children can achieve improved stability and reduced hospitalization rates when supported by multidisciplinary teams (4).

Category	Details
Indications	* Amyotrophic Lateral Sclerosis (ALS) with bulbar involvement * Central hypoventilation syndromes (e.g., CCHS) * Severe restrictive thoracic diseases * Chronic hypercapnic respiratory failure unresponsive to NIV
Requirements	* Tracheostomy care and suctioning * Continuous pulse oximetry and capnography monitoring * Backup ventilator and battery power * Constant caregiver or nursing presence * Supplemental oxygen or feeding tubes in select cases

Table 2. Invasive Mechanical Ventilation (IMV): Indications and Requirements

Hybrid & Specialized Ventilation Modes

Some patients benefit from hybrid ventilation strategies where both non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV) are employed in a circadian or disease-stage-dependent pattern. For instance, nocturnal NIV can be used alongside daytime IMV. This approach is particularly relevant in pediatric neuromuscular conditions or during transitions from partial to full ventilatory dependence (3).

Advanced ventilator technologies are increasingly being integrated into HMV. Neurally Adjusted Ventilatory Assist (NAVA), for example, detects diaphragm electrical signals (EAdi) to precisely tailor pressure delivery to patient effort. This mode has shown significant promise in improving synchrony and enhancing extubation success in neonates, and its potential for long-term home use is currently under consideration (12). Similarly, volume-assured modes like iVAPS and AVAPS automatically adjust pressures to maintain set ventilation targets, proving highly beneficial in patients with irregular breathing patterns or progressive disease.

Mouthpiece ventilation (MPV) remains an essential option for patients who require intermittent support during wakeful hours. This method uniquely preserves the ability to speak, eat, and interact—critical factors for maintaining autonomy and quality of life in conditions such as Amyotrophic Lateral Sclerosis (ALS) and other high-functioning neuromuscular disorders (NMDs) (11).

Hybrid NIV+IMV: Combines non-invasive and invasive support based on time of day or disease progression.
NAVA: Improves patient-ventilator synchrony and comfort by sensing diaphragm activity.
iVAPS and AVAPS: Automatically adjust ventilator support to meet changing patient demands and maintain ventilation targets.
MPV: Enhances autonomy and communication for awake patients requiring intermittent support.

Ventilator Technology and Equipment

The rise of compact and intelligent ventilators has profoundly revolutionized home mechanical ventilation (HMV). Modern devices, offer a comprehensive range of ventilatory modes (including both pressure- and volume-controlled), enhanced portability, and continuous monitoring capabilities. These advancements translate into quieter operation, improved energy efficiency, and a design suited for long-term use, spanning months to years (1).

Key technological enhancements include real-time alarms for critical events like apnea, circuit disconnection, and excessive leaks. Furthermore, these devices often feature programmable day/night cycles for optimized therapy and are fully compatible with essential oxygen and humidification systems. The integration of telehealth functionalities is a significant step forward, enabling clinicians to remotely adjust ventilator settings, download vital adherence data, and proactively intervene in cases of patient deterioration (5).

Despite these substantial advantages, equitable access to modern ventilators and integrated telemonitoring tools remains a significant challenge, particularly in low-resource regions. To ensure safe and truly global HMV deployment, there is a pressing need for the development of simpler, more ruggedized devices, alongside sustained investment in comprehensive caregiver training programs (8).

Key Features of Modern Home Ventilators:

Customizable Modes: Offers diverse pressure- and volume-controlled ventilation modes for personalized therapy.
Integrated Safety: Features built-in real-time alarms and robust safety systems (e.g., for apnea, disconnection, leaks).
Data Connectivity: Enables comprehensive data logging and wireless connectivity for remote monitoring.
Telehealth Capabilities: Supports remote setting adjustments by clinicians and early intervention based on downloaded adherence data.
System Compatibility: Designed for seamless integration with humidifiers, supplemental oxygen, and other essential accessories.

Feature	Non-Invasive Ventilation (NIV)	Invasive Mechanical Ventilation (IMV)
Interface	Nasal/oronasal/full-face mask, mouthpiece	Tracheostomy tube
Invasiveness	Non-invasive	Surgical airway required
Patient comfort	Generally better	Less comfortable
Risk of infection	Low (e.g., skin breakdown, conjunctivitis)	High (e.g., ventilator-associated pneumonia, tracheitis)
Monitoring needs	Moderate (e.g., adherence, basic vitals)	Intensive (e.g., continuous capnography, frequent suctioning)
Caregiver demand	Moderate	High (often requires 24/7 skilled support)
Training requirements	Basic respiratory care and device operation	Advanced care for tracheostomy, ventilator, and emergency scenarios
Portability	Highly portable	Portable with more extensive equipment needed
Use in Pediatrics	Yes	Yes (with significantly increased resources and supervision)
Common Indications	COPD, OHS, ALS (non-bulbar onset), SMA, restrictive thoracic diseases	Bulbar ALS, central hypoventilation, severe tracheomalacia, failed NIV

Table 3. Comparison Between Non-Invasive Ventilation (NIV) and Invasive Mechanical Ventilation (IMV)

Mode	Full Name	Clinical Use Case	Advantages
CPAP	Continuous Positive Airway Pressure	Obstructive Sleep Apnea (OSA), mild Obesity Hypoventilation Syndrome (OHS)	Simple, effective for upper airway support and maintaining patency
BiPAP	Bilevel Positive Airway Pressure	Chronic Obstructive Pulmonary Disease (COPD), OHS, Neuromuscular Diseases (NMDs) with hypoventilation	Supports both inspiration (IPAP) and expiration (EPAP)
AVAPS/VAPS	(Average) Volume-Assured Pressure Support	Progressive NMDs (e.g., Amyotrophic Lateral Sclerosis [ALS], Duchenne Muscular Dystrophy [DMD])	Guarantees a target tidal volume, improves patient-ventilator synchrony
S/T Mode	Spontaneous/Timed Mode	Patients with irregular or absent respiratory drive (e.g., Congenital Central Hypoventilation Syndrome [CCHS])	Provides a backup respiratory rate in case of apnea or insufficient spontaneous effort
iVAPS	Intelligent Volume-Assured Pressure Support	Progressive or variable conditions with fluctuating ventilatory needs	Automatically adapts pressure support to maintain ventilation targets based on real-time feedback

Table 4. Common Ventilation Modes in Home NIV

Condition	Preferred Modality	Comments
COPD with chronic hypercapnia	NIV (BiPAP, iVAPS)	Proven to reduce mortality and hospitalizations (e.g., ERS guidelines)
Obesity Hypoventilation Syndrome (OHS)	NIV (CPAP/BiPAP)	CPAP for OSA-predominant OHS; BiPAP for those with significant daytime hypercapnia
ALS (non-bulbar onset)	NIV (BiPAP, AVAPS)	NIV as first-line; mouthpiece ventilation is an option for daytime support
ALS (bulbar involvement)	IMV	Requires tracheostomy due to high aspiration risk and inability to manage secretions
Congenital Central Hypoventilation Syndrome (CCHS)	IMV	Usually requires 24/7 ventilatory support with tracheostomy from early life
Pediatric NMD (e.g., SMA, DMD)	NIV → IMV (as needed)	Often starts with NIV; progression to IMV based on bulbar function deterioration or respiratory failure

Table 5. Indications for Home Mechanical Ventilation by Condition and Modality

Feature	Description
Ventilation modes	Multiple advanced modes (CPAP, BiPAP, AVAPS, pressure/volume control, S/T, iVAPS)
Portability	Lightweight, compact, battery-operated for 6–12+ hours of independent use
Safety alarms	Integrated alerts for leak detection, apnea, disconnection, and power failure
Data monitoring	On-device storage and seamless wireless/cloud-based uploads for therapy review
Telemonitoring support	Remote setting adjustment by clinicians and real-time patient compliance tracking
Compatibility	Works seamlessly with oxygen concentrators, humidifiers, and various tracheostomy circuits
User interface	Intuitive color screen, touch display, and programmable day/night modes for ease of use
Examples	Philips Trilogy Evo, ResMed Astral, Breas Vivo 50, LTV 1200

Table 6. Key Features of Modern Home Ventilators

Clinical Indications & Patient Populations

Home mechanical ventilation (HMV) is now a cornerstone of chronic respiratory failure (CRF) management across diverse clinical populations. This includes individuals with neuromuscular disorders (NMDs), chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), central hypoventilation syndromes, and severe restrictive thoracic deformities. Increasingly, pediatric populations are also included, particularly children with congenital conditions or progressive respiratory muscle weakness.

Appropriate patient selection is essential to avoid complications and optimize benefits. According to Park and Suh (2020), successful HMV implementation requires physiological evidence of chronic hypoventilation (e.g., daytime PaCO₂ > 45 mmHg), poor sleep quality, declining pulmonary function (e.g., forced vital capacity [FVC] < 50%), or frequent respiratory exacerbations (13). Studies from Canada, Europe, and Asia consistently confirm that timely HMV initiation improves survival, increases hospital-free days, and enhances the quality of life in eligible patients (14, 15).

Chronic Obstructive Pulmonary Disease (COPD)

Home mechanical ventilation (HMV) has become standard in managing severe Chronic Obstructive Pulmonary Disease (COPD), particularly for patients with persistent hypercapnia (PaCO₂ > 52 mmHg), especially following acute exacerbations.

The landmark HOT-HMV trial and subsequent reviews confirmed significant reductions in mortality and rehospitalization rates when high-intensity non-invasive ventilation (NIV) is applied post-discharge (16, 17). Modes like Average Volume-Assured Pressure Support (AVAPS) and BiPAP-Spontaneous/Timed (BiPAP-ST) are often utilized to improve ventilation efficiency and optimize nocturnal gas exchange in this population.

Key findings regarding HMV in COPD:

High-intensity NIV demonstrably improves survival in severe COPD.
AVAPS specifically adapts to ventilatory demand and has been shown to reduce CO₂ more effectively than conventional pressure support modes.

The best candidates for HMV in COPD are typically hypercapnic patients recovering from an acute exacerbation.

Obesity Hypoventilation Syndrome (OHS)

Obesity Hypoventilation Syndrome (OHS), characterized by a Body Mass Index (BMI) over 30 kg/m² and a partial pressure of carbon dioxide (PaCO₂) exceeding 45 mmHg, is frequently accompanied by obstructive sleep apnea (OSA). Research indicates that Bilevel Positive Airway Pressure (BiPAP) or Average Volume-Assured Pressure Support (AVAPS) provides superior carbon dioxide (CO₂) control and reduces daytime somnolence. Continuous Positive Airway Pressure (CPAP) remains a viable option for milder OHS cases, particularly when OSA is the predominant issue. Duiverman (2021) highlighted the critical role of early diagnosis and remote monitoring in ensuring long-term patient adherence to therapy (18).

Clinical Highlights:

CPAP is the first-line treatment for OHS that’s predominantly driven by Obstructive Sleep Apnea (OSA).
NIV (BiPAP/AVAPS) is necessary for patients with persistent hypercapnia or those experiencing ventilatory decompensation.
Monitoring adherence is crucial for the long-term success of HMV in OHS patients.

Neuromuscular Diseases (NMDs)

HMV is life-prolonging in progressive NMDs like ALS, SMA, Duchenne Muscular Dystrophy (DMD), and Myotonic Dystrophy. NIV (BiPAP or AVAPS) is started when FVC falls below 50%, or nocturnal hypoventilation symptoms emerge. For advanced ALS with bulbar dysfunction, tracheostomy with IMV is indicated (7).

Innovative strategies such as mouthpiece ventilation (MPV) promote daytime independence without impeding speech or eating. Chowdhury et al. (2024) reported that MPV improves quality of life in high-functioning ALS patients (11).

Central Hypoventilation Syndromes

These include congenital central hypoventilation syndrome (CCHS) and acquired forms due to brainstem injury or tumors. IMV through tracheostomy is the standard in infants and young children. However, NIV may be used in older children as respiratory control improves (3, 15).

Key considerations:

Requires long-term ventilation, often 24/7.
Advanced monitoring (capnography, telemetry) is crucial for safety.
Transition planning needed in adolescence.

Restrictive Chest Wall Disorders

Patients with kyphoscoliosis, post-polio syndrome, or thoracoplasty experience reduced chest wall compliance, leading to nocturnal hypoventilation. BiPAP and volume-assured pressure modes improve sleep quality, gas exchange, and reduce nocturnal desaturation.

Pediatric Indications

Pediatric use of HMV is expanding, particularly for children with bronchopulmonary dysplasia (BPD), tracheobronchomalacia, and neuromuscular or metabolic disorders. Siddaiah et al. (2025) and Czajkowska-Malinowska et al. (2022) observed marked improvement in survival and caregiver satisfaction in home-ventilated children (4, 19). Pediatric patients often require 24-hour IMV, humidification, suctioning, and complex emergency support protocols.

Disease	Ventilation Type	Preferred Mode	Clinical Notes
COPD (severe hypercapnic)	NIV	BiPAP, AVAPS	Start post-exacerbation
Obesity Hypoventilation Syndrome	NIV	CPAP → BiPAP/AVAPS	CPAP in OSA; BiPAP for hypercapnia
ALS (non-bulbar)	NIV → MPV	BiPAP, MPV	Tracheostomy in bulbar onset
ALS (bulbar involvement)	IMV	Volume or pressure control	Requires intensive care
CCHS	IMV → NIV (age-based)	S/T or pressure modes	24-hour support often required
Kyphoscoliosis	NIV	BiPAP, iVAPS	Improves sleep and gas exchange
Pediatric BPD/tracheomalacia	IMV	Pressure control	Home-based PICU setup needed

Table 7. Summary of HMV Indications and Clinical Recommendations

Referances

Fagondes, S. C., da Silva, C. L. O., Hoffmann, A., & colleagues. (2025). Home mechanical ventilation: A narrative review and a proposal of practical approach. Brazilian Journal of Pulmonology. https://doi.org/10.1016/j.jornaldepneumologia.2024.11.003
Scheller, L. L. (2025). Neighborhood-level disparities and health outcomes among children on long-term mechanical ventilation via tracheostomy. eScholarship, University of California. https://escholarship.org/uc/item/75p0v02n
Perez, G. F. (2024). Management strategies for long-term pediatric mechanical ventilation. In Prolonged and Long-Term Mechanical Ventilation in Pediatrics (pp. 47–64). Springer. https://doi.org/10.1007/978-981-97-8903-0_3
Siddaiah, R., McKinney, R. L., House, M. A., & colleagues. (2025). Outcomes of ventilator‐dependent children with severe bronchopulmonary dysplasia and tracheobronchomalacia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71100
Ong, W. H., Ireland, P., Ho, C. K., & colleagues. (2025). Transcutaneous CO₂ measurement in an adult long-term ventilation (LTV) service. Journal of Clinical Medicine, 14(12), 4137. https://doi.org/10.3390/jcm14124137
Morrison, S., Gavey, R., Moman, A., Kwiatkowski, S., Duce, B., Hukins, C., & Ellender, C. (2024). P066 Long-term outcomes from home invasive mechanical ventilation in Queensland. Sleep Advances: A Journal of the Sleep Research Society, 5(Suppl 1), A51–A52. https://doi.org/10.1093/sleepadvances/zpae070.148
Toussaint, M., Wijkstra, P. J., McKim, D., Benditt, J., Winck, J. C., Nasiłowski, J., & Borel, J. C. (2022). Building a home ventilation programme: population, equipment, delivery and cost. Thorax, 77(11), 1140–1148. Advance online publication. https://doi.org/10.1136/thoraxjnl-2021-218410
Yalwar, A., & Sarkar, G. C. (2025). Cost-effective Bluetooth technology-based emergency medical ventilator for respiratory support: A review. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.5289358
Wei, Y. J., Dai, S. J., Chen, Y. J., & Lin, Y. J. (2025). Development and use of home ventilators for pediatric care. Pediatric Respirology and Critical Medicine. https://journals.lww.com/prcm/_layouts/15/oaks.journals/downloadpdf.aspx?an=02088913-202504000-00003
Enzer, K. G., Dawson, J. A., Langevin, J. A., & colleagues. (2025). Medical and social factors associated with prolonged length of stay for chronically ventilated children. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27320
Chowdhury, A. M., Draicchio, D., & Goodin, C. (2024). Patient-reported outcomes of mouthpiece ventilation in neuromuscular conditions. Thorax, 79(Suppl 2), A55.2. https://thorax.bmj.com/content/thoraxjnl/79/Suppl_2/A55.2.full.pdf
Louie, K., Amatya, S., Alpan, G., & Parton, L. A. (2024). Non-invasive ventilation with neurally adjusted ventilatory assist (NAVA) improves extubation outcomes in extremely low-birth-weight infants. Children, 11(10), 1184. https://doi.org/10.3390/children11101184
Park, S., & Suh, E. S. (2020). Home mechanical ventilation: back to basics. Acute and critical care, 35(3), 131–141. https://doi.org/10.4266/acc.2020.00514
MacIntyre, E. J., Asadi, L., & McKim, D. A. (2016). Clinical outcomes associated with home mechanical ventilation. Canadian Respiratory Journal, 2016, 6547180. https://doi.org/10.1155/2016/6547180
Kotanen, P. (2023). Home mechanical ventilation and long-term oxygen treatment – prevalence and survival. Helsingin yliopisto. https://helda.helsinki.fi/bitstream/handle/10138/355572/Kotanen_Petra_dissertation_2023.pdf?sequence=1&isAllowed=y
Murphy, P. B., Rehal, S., Arbane, G., Bourke, S., Calverley, P. M. A., Crook, A. M., Dowson, L., Duffy, N., Gibson, G. J., Hughes, P. D., Hurst, J. R., Lewis, K. E., Mukherjee, R., Nickol, A., Oscroft, N., Patout, M., Pepperell, J., Smith, I., Stradling, J. R., Wedzicha, J. A., … Hart, N. (2017). Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA, 317(21), 2177–2186. https://doi.org/10.1001/jama.2017.4451
Jen, R., Ellis, C., Kaminska, M., et al. (2023). Noninvasive HMV for stable hypercapnic COPD: Canadian Review. Canadian Respiratory Journal, 2023, 8691539. https://doi.org/10.1155/2023/8691539
Duiverman, M. L. (2021). Home mechanical ventilation: setup and monitoring protocols. Pulmonology, 27(1), 1–9. https://doi.org/10.1016/j.pulmoe.2020.08.002
Czajkowska-Malinowska, M., Bartolik, K., et al. (2022). Development of home mechanical ventilation in Poland: 2009–2019. Journal of Clinical Medicine, 11(8), 2098. https://doi.org/10.3390/jcm11082098

Invasive and Non-Invasive Ventilation: Neonatal Respiratory Support

July 16, 2025

by admin ICU Ventilator

Neonatal respiratory failure remains a primary cause of admission to neonatal intensive care units (NICUs) worldwide. Premature birth, affecting an estimated 15 million neonates annually globally, is strongly correlated with pulmonary immaturity and an elevated risk of respiratory complications (1). In such cases, respiratory support is frequently indispensable for reducing morbidity and improving survival outcomes.

Common causes of neonatal respiratory insufficiency include respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), pneumonia, and apnea of prematurity. Without timely intervention, these conditions can lead to rapid clinical deterioration and significant long-term sequelae, such as bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), or mortality.

The physiological immaturity of the neonatal lung significantly contributes to the high incidence of respiratory complications in preterm and term neonates with perinatal distress. In premature infants, incomplete alveolarization and insufficient surfactant production often lead to alveolar collapse.

These factors, coupled with a compliant chest wall, underdeveloped respiratory musculature, and increased oxygen demands, create a scenario where neonates are prone to atelectasis, hypoventilation, and respiratory failure (2). Consequently, mechanical or non-invasive ventilatory support is frequently initiated shortly after birth to stabilize gas exchange and reduce the work of breathing.

Over the past few decades, the field of neonatal respiratory support has evolved dramatically. Mechanical ventilation, once the cornerstone of neonatal respiratory care, has increasingly been supplanted by lung-protective strategies designed to minimize the risks of ventilator-induced lung injury (VILI).

Innovations such as volume-targeted ventilation (VTV), high-frequency oscillatory ventilation (HFOV), and neurally adjusted ventilatory assist (NAVA) have significantly improved synchronization and pressure control. Parallel advances in monitoring technology, including electrical impedance tomography (EIT) and artificial intelligence (AI)-based ventilator analytics, now offer real-time, individualized feedback for optimized care (3).

This review aims to provide a comprehensive overview of current strategies and innovations in neonatal respiratory support. It covers the physiological basis for respiratory assistance in neonates, details conventional and emerging ventilatory approaches, and explores the implications of novel technologies.

Additionally, it discusses the persistent challenges encountered in low-resource settings and outlines future directions for research and clinical practice. Through this review, we seek to inform clinicians, researchers, and policymakers about the current state and future potential of neonatal respiratory care worldwide.

Physiology and Pathophysiology in Neonatal Respiratory

The transition from intrauterine to extrauterine life presents substantial respiratory challenges for neonates, particularly those born prematurely. In utero, gas exchange occurs via the placenta, with the fetal lungs remaining fluid-filled and relatively inactive.

At birth, this abruptly changes, necessitating rapid clearance of lung fluid, the onset of spontaneous breathing, and functional pulmonary circulation. The success of this transition is highly dependent on lung maturity, surfactant availability, and coordinated cardiorespiratory function.

Lung development progresses through several distinct stages: embryonic, pseudoglandular, canalicular, saccular, and alveolar. Alveolarization—the formation of functional gas-exchange units—begins around 36 weeks of gestation and continues postnatally.

In preterm infants, especially those born before 32 weeks, alveolar and capillary networks are insufficiently developed to support efficient gas exchange (2). This underdevelopment contributes to poor lung compliance, increased airway resistance, and ineffective ventilation.

One of the most critical deficits in preterm lung function is the lack of surfactant, a lipoprotein complex that reduces surface tension and prevents alveolar collapse. Surfactant deficiency leads to decreased lung compliance, atelectasis, and impaired oxygenation—the hallmark features of Respiratory Distress Syndrome (RDS).

Additionally, the neonatal chest wall is highly compliant, offering little resistance to inward recoil, and the diaphragm is relatively underpowered, further limiting ventilation efficiency.

Several pathophysiological conditions arise from these anatomical and functional limitations. Transient Tachypnea of the Newborn (TTN) is common in term and near-term infants and is caused by delayed absorption of fetal lung fluid.

In contrast, apnea of prematurity results from the immaturity of brainstem respiratory centers, leading to episodic cessation of breathing. While the underlying mechanisms differ for these conditions, both may necessitate some form of respiratory assistance, whether invasive or non-invasive.

In addition to pulmonary immaturity, hemodynamic and systemic challenges—such as persistent pulmonary hypertension of the newborn (PPHN), patent ductus arteriosus (PDA), or sepsis—can compound respiratory compromise. Hypoxemia and acidosis further increase pulmonary vascular resistance, worsening oxygenation and potentially causing right-to-left shunting.

Collectively, these factors explain why many neonates, especially those born prematurely or with perinatal complications, require respiratory support. Understanding the unique physiology and vulnerabilities of the neonatal lung is essential for selecting the appropriate support strategy and optimizing outcomes.

Condition	Gestational Age Affected	Pathophysiology	Clinical Features	CXR Findings	Initial Management	Need for Respiratory Support
Respiratory Distress Syndrome (RDS)	<32 weeks (mostly preterm)	Surfactant deficiency → alveolar collapse → poor gas exchange	Tachypnea, grunting, nasal flaring, cyanosis	Ground-glass opacities, air bronchograms	Surfactant, CPAP or MV, oxygen	High – often needs MV and surfactant
Transient Tachypnea of the Newborn (TTN)	Term or near-term	Delayed lung fluid clearance → mild pulmonary edema	Tachypnea shortly after birth, no distress signs	Prominent vascular markings, fluid in fissures	Observation, oxygen if needed	Low – usually resolves within 48–72 hrs
Apnea of Prematurity	<34 weeks	Immature central respiratory control → intermittent apnea	Episodes of apnea with bradycardia/desaturation	Often normal	Caffeine, CPAP in moderate/severe cases	Variable – often needs nasal CPAP
Meconium Aspiration Syndrome (MAS)	Term or post-term	Airway obstruction + inflammation → V/Q mismatch, hypoxemia	Respiratory distress, barrel chest, coarse crackles	Patchy infiltrates, hyperinflation	Oxygen, CPAP or MV, sometimes surfactant	Moderate – depends on severity
Persistent Pulmonary Hypertension (PPHN)	Term, near-term	Failure of normal pulmonary vasodilation → right-to-left shunting	Cyanosis unresponsive to O₂, loud second heart sound	Normal or variable	Oxygen, iNO, MV, sedation	High – may require HFOV or ECMO
Bronchopulmonary Dysplasia (BPD)	Very preterm, typically evolving	Chronic lung injury from prolonged O₂/MV exposure	Ongoing oxygen need >28 days, wheezing, poor growth	Hyperinflation, fibrosis, cystic changes	Diuretics, bronchodilators, O₂	Chronic support — often home O₂ or ventilation

Notes: CXR = Chest X-Ray: MV = Mechanical Ventilation: CPAP = Continuous Positive Airway Pressure: iNO = Inhaled Nitric Oxide: O₂ = Supplemental Oxygen

Invasive Ventilatory Support

Invasive mechanical ventilation (IMV) is a critical intervention for neonates with life-threatening respiratory failure, often due to surfactant deficiency, structural lung immaturity, or systemic complications such as sepsis or persistent pulmonary hypertension.

While IMV can be life-saving, it is associated with significant risks, necessitating careful selection of ventilatory modes, parameters, and weaning strategies to optimize outcomes and reduce harm (4, 5).

Invasive Ventilation Modes and Strategies

Several ventilatory modes are used in neonatal intensive care units (NICUs), each tailored to specific clinical needs:

Assist-Control Ventilation (A/C): Delivers preset breaths, which can be initiated by the neonate or the ventilator. While maintaining adequate minute ventilation, this mode carries an increased risk of asynchrony and volutrauma (lung injury caused by excessive tidal volumes).
Synchronized Intermittent Mandatory Ventilation (SIMV): Synchronizes mandatory breaths with spontaneous respiratory efforts, improving patient comfort and reducing the risk of hyperventilation.
Volume-Targeted Ventilation (VTV): Automatically adjusts pressure to deliver consistent tidal volumes. Studies indicate that VTV reduces the incidence of bronchopulmonary dysplasia (BPD), hypocarbia, and intraventricular hemorrhage compared to pressure-limited modes (6, 7).
High-Frequency Oscillatory Ventilation (HFOV): Utilizes rapid oscillations at small tidal volumes, thereby maintaining lung recruitment while minimizing barotrauma. Newer strategies now emphasize volume targeting during HFOV, leading to better control of CO₂ and improved outcomes (7, 8).

Lung-Protective Strategies

Modern neonatal ventilation prioritizes lung protection by minimizing injury from overdistension and repetitive collapse-reopening:

Permissive Hypercapnia: This strategy tolerates moderate hypercapnia to reduce ventilation pressures and associated lung injury.
Open Lung Strategy: This approach incorporates lung recruitment maneuvers and optimal PEEP (Positive End-Expiratory Pressure) titration to prevent atelectasis and minimize dynamic strain (9).
Volume Guarantee Modes: Integrated into many modern ventilators, these modes ensure the delivery of targeted volumes during each breath, regardless of compliance changes.

Innovations such as artificial intelligence (AI)-guided pressure titration and real-time electrical impedance tomography (EIT) are increasingly integrated to personalize lung protection strategies (2, 3).

Risks and Adverse Outcomes

Invasive mechanical ventilation (IMV) is associated with several short- and long-term complications, including:

Ventilator-Induced Lung Injury (VILI): This encompasses barotrauma, volutrauma, atelectrauma, and biotrauma, all of which are primary contributors to bronchopulmonary dysplasia (BPD).
Ventilator-Associated Pneumonia (VAP): A significant nosocomial infection risk that can prolong NICU stay and worsen outcomes.
Laryngeal and Airway Injury: Prolonged intubation can lead to subglottic stenosis and tracheomalacia, particularly in very low birth weight (VLBW) infants.
Chronic Lung Disease: Up to 50% of preterm infants requiring prolonged IMV develop BPD, with lasting implications for pulmonary and neurodevelopment (10).

Extubation and Weaning in Neonates

The transition from invasive mechanical ventilation (IMV) to spontaneous breathing is a critical juncture in neonatal respiratory care. Premature or failed extubation can lead to increased morbidity, prolonged hospital stays, and a higher risk of complications such as ventilator-associated pneumonia (VAP), airway trauma, and bronchopulmonary dysplasia (BPD) (11). Therefore, the timing and strategy for weaning and extubation must be both evidence-based and individualized.

Physiological Readiness for Extubation

Successful extubation depends on the maturity and coordination of respiratory control, adequate gas exchange, and respiratory muscle endurance. Clinicians assess multiple physiological parameters before attempting extubation, including:

Adequate Spontaneous Respiratory Drive: Demonstrated by consistent respiratory effort with an acceptable respiratory rate.
Stable Gas Exchange: Pre-extubation arterial blood gases should show a pH > 7.25, PaCO₂ < 60 mmHg (for most neonates), and SpO₂ in the target range on an FiO₂ < 0.4.
Minimal Ventilator Support: Indicated by peak inspiratory pressure (PIP) < 20 cmH₂O, PEEP ≤ 5 cmH₂O, and mean airway pressure (MAP) within safe limits.
Hemodynamic Stability: Absence of significant cardiovascular instability, apnea, or bradycardia episodes.

Premature infants are especially vulnerable to extubation failure due to underdeveloped respiratory musculature, immature central respiratory control, and a highly compliant chest wall (12).

Clinical Predictors and Tools

While there is no universally accepted extubation readiness index, several approaches have shown promise:

Spontaneous Breathing Trials (SBTs): Typically lasting 3–5 minutes, SBTs assess the neonate’s ability to breathe spontaneously with minimal pressure support. Success in SBTs correlates strongly with extubation success in older infants but has mixed predictive value in preterm infants (13).
Extubation Readiness Scores (ERS): Composite tools incorporating variables like gestational age, respiratory pattern, minute ventilation, and neurological status are under investigation to standardize assessments (3).
Diaphragmatic Ultrasound and EIT: Novel non-invasive imaging modalities such as diaphragmatic excursion measurement and electrical impedance tomography (EIT) can aid in assessing respiratory effort and lung aeration prior to extubation (2).

Weaning Strategies

Weaning protocols can be gradual or abrupt, depending on the patient’s underlying condition, lung maturity, and ventilator settings. Common strategies include:

Stepwise Reduction: This involves progressively decreasing ventilator support parameters (e.g., Peak Inspiratory Pressure [PIP], respiratory rate, FiO₂) while continuously monitoring for signs of distress or desaturation.
Mode Transitioning: This strategy involves transitioning from synchronized intermittent mandatory ventilation (SIMV) or assist-control (A/C) to pressure support ventilation (PSV) or continuous positive airway pressure (CPAP) before extubation.
Volume Guarantee Titration: Ensuring the delivery of a minimum tidal volume, even during low spontaneous effort, helps prevent underventilation before extubation.

Extubation Failure and Its Implications

Extubation failure—defined as the need for reintubation within 48–72 hours—occurs in up to 30–40% of extremely preterm infants. Risk factors include:

Birth weight < 1000g
Gestational age < 28 weeks
History of sepsis or intraventricular hemorrhage (IVH)
High FiO₂ (> 0.5) at the time of extubation
Poor weight gain or neuromuscular tone

The consequences of failed extubation are significant: repeated intubation increases the risk of vocal cord injury, subglottic stenosis, and worsens lung inflammation, potentially exacerbating bronchopulmonary dysplasia (BPD) (9, 11).

To mitigate this risk, post-extubation support strategies include the early use of non-invasive ventilation (e.g., nasal continuous positive airway pressure [nCPAP], bilevel positive airway pressure [BiPAP], high-flow nasal cannula [HFNC]) and pharmacologic agents like caffeine citrate, which has been shown to reduce apnea and improve extubation outcomes in preterm infants (10).

Non-Invasive Ventilation Strategies in Neonatal Respiratory

Non-invasive ventilation (NIV) plays a pivotal role in neonatal respiratory support, particularly in preterm infants, by providing respiratory assistance while avoiding the risks associated with endotracheal intubation. The primary goal of NIV is to maintain adequate gas exchange, reduce the work of breathing, and prevent lung injury associated with invasive ventilation. Over the past two decades, this field has evolved significantly, offering a range of NIV modalities with improved patient outcomes.

Modes of Non-Invasive Ventilation

Nasal Continuous Positive Airway Pressure (nCPAP) is the most widely used non-invasive technique in neonatal units. It operates by maintaining a constant distending pressure in the airways, thereby preventing alveolar collapse, improving functional residual capacity, and decreasing the work of breathing.

NCPAP is particularly effective in the early management of Respiratory Distress Syndrome (RDS) and has been shown to reduce the need for mechanical ventilation and the risk of bronchopulmonary dysplasia (14).

Nasal Intermittent Positive Pressure Ventilation (NIPPV) and its variant, Bilevel Positive Airway Pressure (BiPAP), deliver intermittent pressure boosts over a CPAP baseline. NIPPV improves minute ventilation, augments tidal volumes, and is especially effective during weaning or post-extubation. Studies indicate that NIPPV reduces extubation failure compared to nCPAP, although its superiority in primary respiratory support is less conclusive (15, 16).

Heated Humidified High-Flow Nasal Cannula (HHHFNC) delivers warmed, humidified air-oxygen blends at flow rates sufficient to wash out nasopharyngeal dead space and provide a low level of positive pressure. Its simplicity, comfort, and ease of use have led to its widespread adoption. However, HHHFNC may provide insufficient support in infants with moderate to severe RDS, particularly those younger than 28 weeks of gestation (17).

Non-invasive Neurally Adjusted Ventilatory Assist (NAVA) utilizes diaphragmatic electromyographic signals to trigger ventilator assistance, offering highly synchronized support. While promising, this modality is currently limited to specialized centers and remains under evaluation in large-scale clinical trials (18).

Interfaces and Delivery Systems

The effectiveness of non-invasive ventilation (NIV) is profoundly influenced by the interface used. Poorly fitted or inappropriate interfaces can lead to pressure leak, ineffective ventilation, or skin injury. A range of nasal interfaces is available, each with unique advantages and trade-offs:

Interface Type	Pressure Delivery	Comfort/Tolerability	Risk of Nasal Trauma	Leak Management	Common Use
Short Binasal Prongs (e.g., Hudson)	Reliable, low resistance	Moderate	High (esp. septal)	Good fit required	CPAP, NIPPV
Nasal Masks	Broad surface area	Moderate–High	Moderate	Lower risk of leak	CPAP, NIPPV
RAM Cannula	Variable pressures	High	Low–Moderate	Prone to leak	Low-level CPAP
Nasopharyngeal Tube	Moderate, stable	Low	High	Minimal leak	CPAP (esp. in LMICs)

There is no definitive consensus on the most effective interface; however, rotating between nasal prongs and masks is widely recommended to prevent skin breakdown (19, 20).

Failure Criteria and Escalation Indicators

Recognizing non-invasive ventilation (NIV) failure early is essential to avoid delays in mechanical ventilation, which are associated with higher morbidity. Failure criteria include:

Arterial pH < 7.25 with PaCO₂ > 65 mmHg
Sustained FiO₂ > 0.4 to maintain SpO₂ targets
Recurrent apnea (>6 episodes/hour) or severe bradycardia
Respiratory muscle fatigue and signs of distress
Hemodynamic instability

Adjuncts such as rescue surfactant therapy—administered via the INSURE (Intubation, Surfactant, Extubation) or LISA (Less Invasive Surfactant Administration) methods—can help reduce the likelihood of NIV failure and progression to mechanical ventilation (17, 21).

Clinical Outcomes and Ongoing Controversies

Non-invasive ventilation (NIV) has been instrumental in reducing rates of intubation, bronchopulmonary dysplasia (BPD), and ventilator-associated complications. However, several debates remain unresolved:

NIPPV vs. CPAP: While evidence supports NIPPV as superior for reducing extubation failure, its effectiveness in avoiding initial intubation is not uniformly conclusive (15).
HFNC as Primary Support: Although user-friendly and well-tolerated, high-flow nasal cannula (HFNC) may be suboptimal for more severe cases of respiratory distress syndrome (RDS) in preterm infants (14, 16).
Nasal Trauma: Nasal skin breakdown remains a significant complication, particularly with prolonged nCPAP use. Preventive measures include hydrocolloid barriers, alternating interfaces, and vigilant skin checks (19).
Protocol Variability: A lack of standardized protocols for the initiation, escalation, and weaning of NIV persists across institutions, highlighting the need for consensus guidelines and further research (22).

References

1. Greenough, A., Alberti, P., & Ade-Ajayi, N. (2025). Respiratory support strategies for surgical neonates: A review. Children, 12(6), Article e1009. https://pmc.ncbi.nlm.nih.gov/articles/PMC11941308/

2. Ako, A. A., Ismaiel, A., & Rastogi, S. (2025). Electrical impedance tomography in neonates: A review. Pediatric Research. https://www.nature.com/articles/s41390-025-03929-x

3. Hsu, J. F., Lin, Y. C., Lin, C. Y., Chu, S. M., & Cheng, H. J. (2025). Deep learning models for early and accurate diagnosis of ventilator-associated pneumonia in mechanically ventilated neonates. Computers in Biology and Medicine, 162, Article 107511. https://www.sciencedirect.com/science/article/pii/S0010482525002938

4. Chakkarapani, A. A., Adappa, R., Ali, S. K. M., & Gupta, S. (2020). Current concepts in assisted mechanical ventilation in the neonate: Part 2. International Journal of Pediatrics and Adolescent Medicine, 7(4), 179–186. https://doi.org/10.1016/j.ijpam.2020.07.006

5. Schulzke SM, Stoecklin B. Update on ventilatory management of extremely preterm infants. Pediatr Anesth. 2022;32(5):432-40. https://doi.org/10.1111/pan.14369

6. Keszler, M. (2017). Volume-targeted ventilation: One size does not fit all. Seminars in Fetal and Neonatal Medicine, 22(6), 369–375. https://doi.org/10.1016/j.siny.2017.08.002

7. Tingay, D. G., Dahm, S. I., & Sett, A. (2025). Are we ready for volume targeting during high-frequency oscillatory ventilation in neonates? Pediatric Research. https://www.nature.com/articles/s41390-025-04015-y

8. Hodgson, C. L., Tuxen, D. V., & Adritsos, D. (2020). Application of new ARDS guidelines at the bedside. Critical Care, 24(1), 1307-16. https://pmc.ncbi.nlm.nih.gov/articles/PMC6591785/

9. Van Kaam, A. H., & Rimensberger, P. C. (2007). Lung-protective ventilation strategies in neonatology: What do we know and what do we need to know? Critical Care Medicine, 35(3), 925–931. https://journals.lww.com/ccmjournal/Abstract/2007/03000/Lung_protective_ventilation_strategies_in.35.aspx

10. Shi, Y., & De Luca, D. (2019). Noninvasive respiratory support strategies after extubation in preterm neonates. BMC Pediatrics, 19, Article 1625. https://doi.org/10.1186/s12887-019-1625-1

11. Ozer, E. A. (2020). Lung-protective ventilation in neonatal intensive care unit. Journal of Clinical Neonatology, 9(3), 105–113. https://10.4103/jcn.JCN_96_19

12. Egbuta, C., & Easley, R. B. (2022). Update on ventilation management in the Pediatric Intensive Care Unit. Pediatric Anesthesia, 32(6), 698–708. https://doi.org/10.1111/pan.14374

13. Colaizy, T. T., Elgin, T. G., Berger, J. N., & Thomas, B. A. (2022). Ventilator management in extremely preterm infants. NeoReviews, 23(10), e661–e671. https://doi.org/10.1542/neo.23-10-e661

14. Shi, Y., Muniraman, H., & Biniwale, M. (2020). A review on non-invasive respiratory support for management of respiratory distress in extremely preterm infants. Frontiers in Pediatrics, 8, Article 270. https://doi.org/10.3389/fped.2020.00270

15. Yuan, G., Liu, H., Wu, Z., & Chen, X. (2021). Comparison of the efficacy and safety of three non-invasive ventilation methods in the initial treatment of premature infants with respiratory distress syndrome. International Journal of Clinical and Experimental Medicine, 14(2), 375–383. https://e-century.us/files/ijcem/14/2/ijcem0116814.pdf

16. More, K., Ramaswamy, V. V., & Roehr, C. C. (2020). Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: systematic review and meta-analysis. Pediatric Pulmonology, 55(6), 1325–1335. https://doi.org/10.1002/ppul.25011

17. Dassios, T., Kaltsogianni, O., & Greenough, A. (2023). Neonatal respiratory support strategies—short and long-term respiratory outcomes. Frontiers in Pediatrics, 11, Article 1212074. https://doi.org/10.3389/fped.2023.1212074

18. Karnati, S., & Sammour, I. (2020). Non-invasive respiratory support of the premature neonate: from physics to bench to practice. Frontiers in Pediatrics, 8, Article 214. https://doi.org/10.3389/fped.2020.00214

19. Boel, L., Hixson, T., Brown, L., Sage, J., & Kotecha, S. (2022). Non-invasive respiratory support in preterm infants. Paediatric Respiratory Reviews, 44, 1–10. https://doi.org/10.1016/j.prrv.2022.01.004

20. Ramaswamy, V. V., Devi, R., & Kumar, G. (2023). Non-invasive ventilation in neonates: a review of current literature. Frontiers in Pediatrics, 11, Article 1248836. https://doi.org/10.3389/fped.2023.1248836

21. Permall, D. L., Pasha, A. B., & Chen, X. (2019). Current insights in non-invasive ventilation for the treatment of neonatal respiratory disease. Italian Journal of Pediatrics, 45, 70. https://doi.org/10.1186/s13052-019-0707-x

22. Hussain, W. A., & Marks, J. D. (2019). Approaches to noninvasive respiratory support in preterm infants: from CPAP to NAVA. NeoReviews, 20(4), e213–e225.

The Role of Mechanical Ventilation in ARF Management

April 11, 2025

by admin ICU Ventilator

Mechanical ventilation plays a critical role in addressing the pathophysiological mechanisms underlying acute respiratory failure (ARF). By correcting gas exchange abnormalities, reducing respiratory muscle workload, and preventing complications, it provides essential support for patients in critical conditions (1,5,7,8). Below, specific mechanisms of mechanical ventilation are linked to the pathophysiological issues they target to enhance clarity and coherence.

Correction of Hypoxemia

One of the primary goals of mechanical ventilation in ARF is to address hypoxemia caused by mechanisms such as ventilation-perfusion (V/Q) mismatch, shunting, or diffusion impairment.

Mechanism: Mechanical ventilation increases the fraction of inspired oxygen (FiO₂), ensuring higher oxygen availability in the alveoli, which is crucial for patients with reduced oxygenation due to pneumonia, ARDS, or pulmonary embolism.
PEEP (Positive End-Expiratory Pressure): PEEP prevents alveolar collapse during exhalation by maintaining positive pressure in the lungs, thereby improving functional residual capacity (FRC). This is particularly effective in conditions involving alveolar instability, such as ARDS or atelectasis.
Link to Pathophysiology: In cases of shunting, where blood bypasses ventilated alveoli, PEEP recruits collapsed alveoli and redistributes ventilation, reducing hypoxemia.

Removal of Hypercapnia

Hypercapnia in ARF arises from hypoventilation or increased dead space, as seen in conditions like COPD exacerbations or severe obesity hypoventilation syndrome.

Mechanism: Mechanical ventilation increases minute ventilation by optimizing tidal volume (VT) and respiratory rate. By enhancing the removal of carbon dioxide, it normalizes arterial pH and relieves respiratory acidosis.
Pressure-Control Ventilation (PCV): PCV is particularly beneficial in hypercapnic ARF as it delivers preset pressure during inspiration, ensuring adequate ventilation while minimizing airway pressures.
Link to Pathophysiology: In hypoventilation-related hypercapnia, increasing ventilatory support reduces carbon dioxide retention, reversing acidemia and preventing hemodynamic instability.

Reduction of Work of Breathing

ARF often places a high workload on respiratory muscles, leading to fatigue and eventual failure, especially in conditions like COPD exacerbations or severe asthma.

Mechanism: Mechanical ventilation reduces the effort required to breathe by delivering positive pressure during inspiration. Modes like pressure support ventilation (PSV) and assist-control ventilation (ACV) enable respiratory muscle rest while maintaining adequate ventilation.
Link to Pathophysiology: By decreasing the work of breathing, mechanical ventilation prevents respiratory muscle exhaustion, a key contributor to hypercapnic ARF.

Alveolar Recruitment and Stabilization

Alveolar recruitment strategies are critical for restoring effective gas exchange in conditions like ARDS, where alveolar collapse and severe V/Q mismatch are common.

Mechanism: PEEP and lung-protective ventilation strategies, such as low tidal volumes, recruit and stabilize alveoli, increasing the surface area available for gas exchange.
Link to Pathophysiology: In ARDS, where alveolar collapse exacerbates shunting, PEEP opens collapsed alveoli, improving oxygenation and reducing the severity of hypoxemia.

Prevention of Secondary Complications

Mechanical ventilation provides controlled respiratory support that reduces the risk of secondary complications such as aspiration, ventilator-associated pneumonia (VAP), or multi-organ failure.

Mechanism: Secure airway management with invasive mechanical ventilation protects against aspiration, while precise ventilator settings minimize barotrauma and ventilator-induced lung injury (VILI).
Link to Pathophysiology: By addressing hypoxemia and hypercapnia, mechanical ventilation prevents systemic complications like hypoxia-induced multi-organ failure and maintains hemodynamic stability.

Mechanical ventilation compensates for the physiological disruptions seen in ARF by targeting specific mechanisms like V/Q mismatch, diffusion impairment, and increased work of breathing. Each intervention, whether optimizing oxygenation, reducing carbon dioxide levels, or stabilizing alveolar function, is tailored to the patient’s underlying pathology.

This ensures effective management of ARF while minimizing complications, emphasizing the indispensable role of mechanical ventilation in critical care settings (1-8,10).

Types of Mechanical Ventilation

Mechanical ventilation is classified into invasive and non-invasive methods, each with specific applications based on the patient’s condition and therapeutic needs (9-11). Both types play a vital role in the management of acute respiratory failure (ARF), with the choice determined by the severity of respiratory dysfunction and the clinical response to treatment (10).

Non-Invasive Ventilation (NIV)

Non-invasive ventilation delivers respiratory support through a mask or nasal interface, avoiding the need for intubation. It is particularly effective in patients with mild to moderate ARF who are conscious and able to protect their airway.

Mechanism: NIV enhances oxygenation and ventilation using positive airway pressure, which prevents alveolar collapse and reduces the work of breathing.
Common Modes:
- Continuous Positive Airway Pressure (CPAP): Maintains constant positive airway pressure throughout the respiratory cycle, improving oxygenation in conditions such as cardiogenic pulmonary edema.
- Bilevel Positive Airway Pressure (BiPAP): Alternates between inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), facilitating both oxygenation and ventilation, particularly in hypercapnic ARF seen in COPD exacerbations.
Clinical Application: NIV is widely used in exacerbations of chronic conditions like COPD, mild ARDS, and heart failure, where it can stabilize gas exchange and reduce the need for intubation.

Invasive Mechanical Ventilation (IMV)

In cases where non-invasive ventilation fails to stabilize ARF or is contraindicated, invasive mechanical ventilation provides controlled respiratory support through an endotracheal or tracheostomy tube.

Mechanism: IMV directly accesses the airway, ensuring precise delivery of oxygen, removal of carbon dioxide, and reduction of respiratory muscle workload. It also facilitates better protection against aspiration in patients with altered mental status or significant secretions.
Common Modes:
- Assist-Control Ventilation (ACV): Delivers a preset tidal volume or pressure with every breath, whether initiated by the patient or the ventilator. ACV provides full respiratory support, ideal for patients with severe ARF and minimal respiratory effort.
- Synchronized Intermittent Mandatory Ventilation (SIMV): Combines mandatory ventilator-delivered breaths with the patient’s spontaneous breaths. It is frequently used during weaning to encourage respiratory muscle activity.
- Pressure Support Ventilation (PSV): Supports spontaneous breathing by delivering a set inspiratory pressure. It is commonly employed during recovery or as a step-down mode in the weaning process.
Clinical Application: IMV is indicated in severe ARF with refractory hypoxemia, hypercapnia unresponsive to NIV, or conditions like ARDS, where invasive strategies like lung-protective ventilation and high PEEP are essential.

Non-invasive ventilation often serves as the first-line treatment in ARF. However, in some cases, such as persistent hypoxemia, rising carbon dioxide levels, or respiratory distress that worsens despite NIV, transitioning to invasive mechanical ventilation becomes necessary to ensure adequate respiratory support and prevent further deterioration (9–11). The specific criteria and clinical scenarios guiding this transition will be examined in a subsequent section.

By tailoring the type of mechanical ventilation to the patient’s condition and response, clinicians can optimize outcomes while minimizing complications.

Modes of Mechanical Ventilation for ARF Treatment

The choice of mechanical ventilation mode in acute respiratory failure (ARF) is determined by the underlying pathology, severity of respiratory compromise, and patient-specific factors (11,12). Optimizing the mode of ventilation is essential to ensure adequate gas exchange while minimizing complications (12). Below, the most commonly used modes are outlined, with an emphasis on their applications and clinical significance.

Assist-Control Ventilation (ACV)

ACV provides full respiratory support by delivering a preset tidal volume (VT) or pressure with each breath, regardless of whether the breath is initiated by the patient or the ventilator.

Application: This mode is typically used in severe ARF, particularly in conditions such as ARDS or pneumonia, where patients may have minimal or absent spontaneous respiratory effort.
Advantages: Guarantees consistent ventilation and simplifies management in critically ill patients.

Synchronized Intermittent Mandatory Ventilation (SIMV)

SIMV delivers a set number of mandatory breaths, synchronized with the patient’s spontaneous respiratory efforts, allowing for unassisted breaths in between.

Application: Often employed as an intermediate step in patients transitioning from full ventilatory support to spontaneous breathing, such as during the weaning process.
Advantages: Promotes respiratory muscle activity while providing a safety net of mandatory ventilator breaths.

Pressure Support Ventilation (PSV)

PSV augments spontaneous breathing by providing a preset level of inspiratory pressure, reducing the effort required for inspiration.

Application: Commonly used in patients with preserved respiratory drive, such as those recovering from ARF or during non-invasive ventilation (NIV).
Advantages: Improves patient comfort, reduces work of breathing, and facilitates weaning from invasive ventilation.

Volume-Controlled and Pressure-Controlled Ventilation (VCV/PCV)

Volume-Controlled Ventilation (VCV) delivers a preset tidal volume, with airway pressure varying depending on lung compliance and resistance.

Application: Used in patients requiring precise control of minute ventilation, such as those with hypercapnia.

Pressure-Controlled Ventilation (PCV) delivers a preset pressure during inspiration, with tidal volume varying based on lung compliance.

Application: Beneficial in patients with reduced lung compliance, such as in ARDS, to limit peak airway pressures and reduce the risk of barotrauma.

High-Frequency Oscillatory Ventilation (HFOV)

HFOV delivers very small tidal volumes at high frequencies, maintaining continuous positive airway pressure.

Application: A rescue strategy for refractory hypoxemia in ARDS when conventional ventilation fails.
Advantages: Minimizes ventilator-induced lung injury (VILI) by preventing alveolar overdistension.

Clinical Significance

The selection of the appropriate mode of mechanical ventilation in ARF is crucial for optimizing outcomes and minimizing complications. For instance, lung-protective ventilation strategies, such as low tidal volume ventilation in ARDS, reduce the risk of ventilator-induced lung injury (11).
Modes like SIMV and PSV play key roles in facilitating weaning and restoring spontaneous respiratory function (11). By tailoring ventilation modes to the individual needs of patients, clinicians can address the specific pathophysiological challenges of ARF while improving survival and recovery rates (11-15).

Advanced Modes of Mechanical Ventilation: ASV, SAV, and NAVA

With the evolution of mechanical ventilation, advanced modes like Adaptive Support Ventilation (ASV), SmartCare/Automated Ventilation (SAV), and Neurally Adjusted Ventilatory Assist (NAVA) have emerged as pivotal tools in modern respiratory care. These modes leverage intelligent algorithms and neural control mechanisms to enhance patient outcomes, improve synchronization, and simplify clinical workflows. Below is a comprehensive discussion of each mode and its clinical significance (23-25).

Adaptive Support Ventilation (ASV)

What is ASV?
ASV is an intelligent mode of mechanical ventilation that automatically adjusts ventilatory support based on the patient’s respiratory mechanics and effort. It uses algorithms to calculate the ideal tidal volume and respiratory rate based on the patient’s predicted body weight, lung compliance, and airway resistance (22-25).
How ASV Works:
- ASV continuously monitors the patient’s spontaneous breathing.
- It dynamically adjusts the inspiratory pressure and ventilatory rate to meet the patient’s metabolic demand while preventing over-distension or atelectasis.
- This mode ensures minimal work of breathing while maintaining target minute ventilation.
Benefits of ASV:
- Automatically reduces support as the patient’s respiratory effort improves, facilitating a smooth transition from controlled to spontaneous breathing.
- Decreases the risk of hyperventilation, barotrauma, and ventilator-induced lung injury (VILI) (23,24).
- Improves patient-ventilator synchrony, reducing discomfort and sedation requirements (24).
Evidence and Clinical Applications:
- Studies have shown ASV to be effective in both acute and chronic respiratory failure. For example, research published in Critical Care (Arnal et al., 2008) demonstrated that ASV reduced ventilation duration compared to traditional modes in post-operative ICU patients (26).
- It is widely used in settings requiring dynamic adaptation, such as weaning and managing variable lung mechanics in conditions like ARDS or COPD exacerbations (27).

SmartCare/Automated Ventilation (SAV)

What is SAV?
SmartCare/Automated Ventilation is a closed-loop ventilation system designed primarily to automate the weaning process. It uses an artificial intelligence algorithm to assess and adjust ventilatory support based on real-time patient parameters (25,28-31).
How SAV Works:
- SAV continuously monitors the patient’s respiratory rate, tidal volume, and end-tidal carbon dioxide (EtCO₂).
- Based on these parameters, it adjusts pressure support levels to ensure adequate ventilation and oxygenation.
- When the algorithm determines that the patient can sustain spontaneous breathing, it suggests readiness for extubation.
Benefits of SAV:
- Speeds up the weaning process by reducing the need for manual adjustments (22-31).
- Prevents premature or delayed extubation by following evidence-based criteria.
- Reduces the workload for ICU staff and standardizes the weaning process.
Evidence and Clinical Applications:
- Clinical trials, such as those published in Intensive Care Medicine (Lellouche et al., 2006), have shown that SmartCare reduces the duration of mechanical ventilation and ICU stay while improving extubation success rates (31).
- SAV is especially useful in ICUs with high patient volumes or variability in care protocols (24-31).

Neurally Adjusted Ventilatory Assist (NAVA)

What is NAVA
Neurally Adjusted Ventilatory Assist (NAVA) is an advanced mode of mechanical ventilation that directly uses the patient’s neural respiratory drive to control ventilatory support. Unlike traditional modes that rely on airway pressure or flow triggers, NAVA is driven by electrical activity in the diaphragm (Edi), offering highly personalized and precise ventilation (25-34).

How NAVA Works?

Edi Catheter:
A specialized nasogastric catheter detects electrical signals from the diaphragm during the patient’s spontaneous breathing efforts.

Signal Processing:
These signals (Edi) are analyzed in real-time to determine the timing, duration, and intensity of inspiratory effort.

Ventilator Response:
The ventilator delivers pressure support proportional to the patient’s effort, ensuring optimal synchronization and avoiding over-assistance or under-assistance.
Advantages of NAVA

Improved Patient-Ventilator Synchrony:
NAVA directly responds to the patient’s neural respiratory signals, eliminating delays and mismatches that occur with pressure or flow triggering.
Reduces asynchrony-related complications, such as ineffective efforts, double triggering, and patient discomfort.

Reduction in Sedation Needs:
By providing natural, synchronized support, NAVA minimizes the discomfort associated with mechanical ventilation, reducing the need for sedatives.

Enhanced Respiratory Muscle Protection:
Unlike traditional modes that can over-assist, leading to respiratory muscle atrophy, NAVA ensures the diaphragm remains active, maintaining muscle strength and endurance.

Personalized Ventilation:
Adapts dynamically to the patient’s changing respiratory demands, particularly in conditions like ARDS, COPD, or neuromuscular disorders.

Clinical Applications of NAVA

ARDS and Acute Respiratory Failure (ARF):
NAVA provides lung-protective ventilation by avoiding overdistension and barotrauma while maintaining synchrony (38).

Neonatal and Pediatric Ventilation:
Especially useful in premature infants and pediatric patients, where synchrony challenges are common with traditional modes (36-37,39-43).

Weaning:
Facilitates a gradual reduction in ventilatory support by responding to the patient’s natural efforts (44-45).

NAVA represents a significant advancement in mechanical ventilation, focusing on precision and patient-centric care by using the diaphragm’s electrical activity to guide support. Its ability to enhance patient-ventilator synchrony, reduce sedation needs, and protect respiratory muscles makes it an invaluable mode in both adult and pediatric populations. When combined with other modes like ASV and SAV, NAVA provides a versatile and comprehensive approach to managing acute respiratory failure.

When to Transition from Non-Invasive Mechanical Ventilation (NIMV) to Invasive Mechanical Ventilation (IMV) in ARF

Non-invasive mechanical ventilation (NIMV) is often the first-line treatment for acute respiratory failure (ARF) in specific conditions like COPD exacerbations or mild-to-moderate hypoxemia. However, in some cases, NIMV may fail to provide adequate support, requiring a transition to invasive mechanical ventilation (IMV) to prevent further deterioration. Here are the key indicators and clinical scenarios to consider transitioning:

1. Worsening Gas Exchange Despite NIMV

Signs:
- Persistent or worsening hypoxemia (PaO₂ < 60 mmHg on FiO₂ ≥ 0.6).
- Rising PaCO₂ (> 50 mmHg) with associated respiratory acidosis (pH < 7.25).
Reason: Indicates that NIMV is insufficient to meet oxygenation or ventilation demands.

2. Severe Respiratory Distress

Signs:
- Increased respiratory rate (> 35 breaths/min).
- Use of accessory muscles, paradoxical breathing, or nasal flaring.
- Inability to speak in full sentences due to dyspnea.
Reason: Suggests that the patient’s work of breathing has exceeded the support provided by NIMV, risking respiratory muscle fatigue and collapse.

3. Altered Mental Status

Signs:
- Confusion, agitation, or inability to cooperate with NIMV.
- Progression to somnolence or coma (indicating hypercapnia or hypoxemia affecting cerebral function).
Reason: Neurological impairment reduces the ability to maintain spontaneous breathing or adhere to NIMV.

4. Hemodynamic Instability

Signs:
- Hypotension (systolic blood pressure < 90 mmHg) unresponsive to fluid resuscitation.
- Shock or signs of reduced cardiac output.
Reason: Indicates systemic compromise that requires better oxygenation and ventilation control via IMV.

5. Risk of Aspiration or Airway Protection Issues

Signs:
- Inability to clear secretions or significant mucus plugging.
- Frequent vomiting or risk of aspiration (e.g., altered consciousness).
Reason: IMV is necessary to secure the airway with an endotracheal tube to prevent aspiration-related complications.

6. Failure to Tolerate NIMV

Signs:
- Poor mask seal due to facial anatomy or agitation.
- Skin breakdown or discomfort causing discontinuation of therapy.
Reason: Intolerance to NIMV can reduce adherence, rendering it ineffective.

7. No Clinical Improvement Within 1–2 Hours of NIMV

Signs:
- Lack of improvement in respiratory rate, gas exchange, or oxygenation after 1–2 hours of optimal NIMV.
Reason: Delaying the switch to IMV increases the risk of respiratory arrest and worsens outcomes.

The decision to switch from NIMV to IMV in ARF should be guided by clinical judgment, monitoring of gas exchange, respiratory mechanics, and overall patient stability. Early recognition of NIMV failure and timely intubation improve outcomes and prevent complications associated with delayed intervention (12-14, 16-21).

References

Kapil S, Wilson JG. Mechanical Ventilation in Hypoxemic Respiratory Failure. Emerg Med Clin North Am. 2019;37(3):431-444. doi:10.1016/j.emc.2019.04.005
Delerme S, Ray P. Acute respiratory failure in the elderly: diagnosis and prognosis. Age Ageing. 2008;37(3):251-257. doi:10.1093/ageing/afn060
Antro C, Merico F, Urbino R, Gai V. Non-invasive ventilation as a first-line treatment for acute respiratory failure: “real life” experience in the emergency department. Emerg Med J. 2005;22(11):772-777. doi:10.1136/emj.2004.018309
Piraino T. Noninvasive Respiratory Support in Acute Hypoxemic Respiratory Failure. Respir Care. 2019;64(6):638-646. doi:10.4187/respcare.06735
Abellan C, Bertin C, Fumeaux T, Carrel L. Insuffisance respiratoire aiguë : prise en charge hospitalière non invasive [Acute respiratory failure : non-invasive hospital management]. Rev Med Suisse. 2020;16(705):1636-1644.
Munshi L, Mancebo J, Brochard LJ. Noninvasive Respiratory Support for Adults with Acute Respiratory Failure. N Engl J Med. 2022;387(18):1688-1698. doi:10.1056/NEJMra2204556
Pisani L, Corcione N, Nava S. Management of acute hypercapnic respiratory failure. Curr Opin Crit Care. 2016;22(1):45-52. doi:10.1097/MCC.0000000000000269
Liu YJ, Zhao J, Tang H. Non-invasive ventilation in acute respiratory failure: a meta-analysis. Clin Med (Lond). 2016;16(6):514-523. doi:10.7861/clinmedicine.16-6-514
Pham T, Brochard LJ, Slutsky AS. Mechanical Ventilation: State of the Art. Mayo Clin Proc. 2017;92(9):1382-1400. doi:10.1016/j.mayocp.2017.05.004
Tobin MJ, Laghi F, Jubran A. Ventilatory failure, ventilator support, and ventilator weaning. Compr Physiol. 2012;2(4):2871-2921. doi:10.1002/cphy.c110030
Tobin, M. J. (2013). Principles and practice of mechanical ventilation, 3e. McGraw-Hill Education LLC.
Pinsky MR. Toward a better ventilation strategy for patients with acute lung injury. Crit Care. 2000;4(4):205-206. doi:10.1186/cc695
Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426. Published 2017 Aug 31. doi:10.1183/13993003.02426-2016
Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50(3):1700582. Published 2017 Sep 10. doi:10.1183/13993003.00582-2017
Oczkowski S, Ergan B, Bos L, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J. 2022;59(4):2101574. Published 2022 Apr 14. doi:10.1183/13993003.01574-2021
Luo F, Annane D, Orlikowski D, et al. Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders. Cochrane Database Syst Rev. 2017;12(12):CD008380. Published 2017 Dec 4. doi:10.1002/14651858.CD008380.pub2
Blumenthal JA, Duvall MG. Invasive and noninvasive ventilation strategies for acute respiratory failure in children with coronavirus disease 2019. Curr Opin Pediatr. 2021;33(3):311-318. doi:10.1097/MOP.0000000000001021
Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain-Barré syndrome. Expert Rev Clin Immunol. 2020;16(11):1053-1064. doi:10.1080/1744666X.2021.1840355
Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults [published correction appears in Thorax. 2017 Jun;72(6):588. doi: 10.1136/thoraxjnl-2015-208209corr1]. Thorax. 2016;71 Suppl 2:ii1-ii35. doi:10.1136/thoraxjnl-2015-208209
Kress JP, O’Connor MF, Schmidt GA. Clinical examination reliably detects intrinsic positive end-expiratory pressure in critically ill, mechanically ventilated patients. Am J Respir Crit Care Med. 1999;159(1):290-294. doi:10.1164/ajrccm.159.1.9805011
Rittayamai N, Katsios CM, Beloncle F, Friedrich JO, Mancebo J, Brochard L. Pressure-Controlled vs Volume-Controlled Ventilation in Acute Respiratory Failure: A Physiology-Based Narrative and Systematic Review. Chest. 2015;148(2):340-355. doi:10.1378/chest.14-3169
Brunner JX, Iotti GA. Adaptive Support Ventilation (ASV). Minerva Anestesiol. 2002;68(5):365-368.
Dai YL, Hsu RJ, Huang HK, et al. Adaptive support ventilation attenuates postpneumonectomy acute lung injury in a porcine model. Interact Cardiovasc Thorac Surg. 2020;31(5):718-726. doi:10.1093/icvts/ivaa157
Buiteman-Kruizinga LA, Mkadmi HE, Schultz MJ, Tangkau PL, van der Heiden PLJ. Comparison of Mechanical Power During Adaptive Support Ventilation Versus Nonautomated Pressure-Controlled Ventilation-A Pilot Study. Crit Care Explor. 2021;3(2):e0335. Published 2021 Feb 15. doi:10.1097/CCE.0000000000000335
Fernández J, Miguelena D, Mulett H, Godoy J, Martinón-Torres F. Adaptive support ventilation: State of the art review. Indian J Crit Care Med. 2013;17(1):16-22. doi:10.4103/0972-5229.112149
Arnal JM, Wysocki M, Nafati C, et al. Automatic selection of breathing pattern using adaptive support ventilation. Intensive Care Med. 2008;34(1):75-81. doi:10.1007/s00134-007-0847-0
Zhu F, Gomersall CD, Ng SK, Underwood MJ, Lee A. A randomized controlled trial of adaptive support ventilation mode to wean patients after fast-track cardiac valvular surgery. Anesthesiology. 2015;122(4):832-840. doi:10.1097/ALN.0000000000000589
Rose L, Schultz MJ, Cardwell CR, Jouvet P, McAuley DF, Blackwood B. Automated versus non-automated weaning for reducing the duration of mechanical ventilation for critically ill adults and children. Cochrane Database Syst Rev. 2014;2014(6):CD009235. Published 2014 Jun 10. doi:10.1002/14651858.CD009235.pub3
Rose L, Schultz MJ, Cardwell CR, Jouvet P, McAuley DF, Blackwood B. Automated versus non-automated weaning for reducing the duration of mechanical ventilation for critically ill adults and children: a cochrane systematic review and meta-analysis. Crit Care. 2015;19(1):48. Published 2015 Feb 24. doi:10.1186/s13054-015-0755-6
Wysocki M, Jouvet P, Jaber S. Closed loop mechanical ventilation. J Clin Monit Comput. 2014;28(1):49-56. doi:10.1007/s10877-013-9465-2
Lellouche F, Mancebo J, Jolliet P, et al. A multicenter randomized trial of computer-driven protocolized weaning from mechanical ventilation. Am J Respir Crit Care Med. 2006;174(8):894-900. doi:10.1164/rccm.200511-1780OC
Shah SD, Anjum F. Neurally Adjusted Ventilatory Assist (NAVA). In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 22, 2023.
Navalesi P, Longhini F. Neurally adjusted ventilatory assist. Curr Opin Crit Care. 2015;21(1):58-64. doi:10.1097/MCC.0000000000000167
Sheng Y, Shao W, Wang Y, Kang X, Hu R. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023;35(11):1229-1232. doi:10.3760/cma.j.cn121430-20230222-00101
Vahedi NB, Ramazan-Yousif L, Andersen TS, Jensen HI. Implementation of Neurally Adjusted Ventilatory Assist (NAVA): Patient characteristics and staff experiences. J Healthc Qual Res. 2020;35(4):253-260. doi:10.1016/j.jhqr.2020.03.008
Mandyam S, Qureshi M, Katamreddy Y, et al. Neurally Adjusted Ventilatory Assist Versus Pressure Support Ventilation: A Comprehensive Review. J Intensive Care Med. 2024;39(12):1194-1203. doi:10.1177/08850666231212807
Sugunan P, Hosheh O, Garcia Cusco M, Mildner R. Neurally-Adjusted Ventilatory Assist (NAVA) versus Pneumatically Synchronized Ventilation Modes in Children Admitted to PICU. J Clin Med. 2021;10(15):3393. Published 2021 Jul 30. doi:10.3390/jcm10153393
Umbrello M, Antonucci E, Muttini S. Neurally Adjusted Ventilatory Assist in Acute Respiratory Failure-A Narrative Review. J Clin Med. 2022;11(7):1863. Published 2022 Mar 28. doi:10.3390/jcm11071863
Beck J, Emeriaud G, Liu Y, Sinderby C. Neurally-adjusted ventilatory assist (NAVA) in children: a systematic review. Minerva Anestesiol. 2016;82(8):874-883.
Minamitani Y, Miyahara N, Saito K, Kanai M, Namba F, Ota E. Noninvasive neurally-adjusted ventilatory assist in preterm infants: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2024;37(1):2415373. doi:10.1080/14767058.2024.2415373
Fang SJ, Su CH, Liao DL, et al. Neurally adjusted ventilatory assist for rapid weaning in preterm infants. Pediatr Int. 2023;65(1):e15360. doi:10.1111/ped.15360
Rossor TE, Hunt KA, Shetty S, Greenough A. Neurally adjusted ventilatory assist compared to other forms of triggered ventilation for neonatal respiratory support. Cochrane Database Syst Rev. 2017;10(10):CD012251. Published 2017 Oct 27. doi:10.1002/14651858.CD012251.pub2
Stein H, Beck J, Dunn M. Non-invasive ventilation with neurally adjusted ventilatory assist in newborns. Semin Fetal Neonatal Med. 2016;21(3):154-161. doi:10.1016/j.siny.2016.01.006
Liu L, Xu X, Sun Q, et al. Neurally Adjusted Ventilatory Assist versus Pressure Support Ventilation in Difficult Weaning: A Randomized Trial. Anesthesiology. 2020;132(6):1482-1493. doi:10.1097/ALN.0000000000003207
Yuan X, Lu X, Chao Y, et al. Neurally adjusted ventilatory assist as a weaning mode for adults with invasive mechanical ventilation: a systematic review and meta-analysis. Crit Care. 2021;25(1):222. Published 2021 Jun 29. doi:10.1186/s13054-021-03644-z

Acute Respiratory Failure: Causes and Mechanisms

December 25, 2024

by admin ICU Ventilator

Acute respiratory failure (ARF) is a critical condition characterized by the respiratory system’s inability to maintain adequate gas exchange, presenting an immediate threat to life. Its etiologies encompass a wide range of conditions, including acute respiratory distress syndrome (ARDS), pneumonia, exacerbations of chronic obstructive pulmonary disease (COPD), and neuromuscular disorders, all necessitating timely and effective intervention.

Acute respiratory failure (ARF) is a life-threatening condition defined by the respiratory system’s inability to maintain adequate gas exchange, resulting in critically low oxygen levels in the blood (hypoxemia), elevated carbon dioxide levels (hypercapnia), or a combination of both (1). ARF can result from diverse etiologies, including acute respiratory distress syndrome (ARDS), pneumonia, chronic obstructive pulmonary disease (COPD) exacerbations, pulmonary embolism, neuromuscular disorders, or trauma (2, 3). These conditions impair the lung’s capacity to oxygenate blood and eliminate carbon dioxide, leading to severe systemic consequences if not managed promptly and effectively.

What is Acute Respiratory Failure?

Acute respiratory failure (ARF) is a medical condition in which the respiratory system fails to perform its primary function of effective gas exchange. This failure leads to inadequate oxygenation of the blood (hypoxemia), impaired elimination of carbon dioxide from the body (hypercapnia), or both (1). ARF can develop rapidly as a result of various underlying pathologies affecting the lungs, airways, chest wall, or central nervous system (2, 3).

ARF is often a life-threatening emergency that necessitates immediate medical intervention to prevent severe complications or death.

Basic Physiology of the Respiratory System

The primary role of the respiratory system is to facilitate gas exchange, ensuring oxygen delivery to tissues and carbon dioxide removal. This process depends on the proper functioning of several components (5–7):

Ventilation: The physical movement of air into and out of the lungs, determined by respiratory muscle effort and airway patency.
Diffusion: The exchange of gases between the alveoli and pulmonary capillaries, driven by partial pressure gradients.
Perfusion: The blood flow through pulmonary capillaries, enabling gas exchange.

In ARF, a disruption in one or more of these components impairs gas exchange:

Hypoxemic ARF: Defined as PaO₂ < 60 mmHg with normal or low PaCO₂, resulting from impaired oxygenation.
Hypercapnic ARF: Defined as PaCO₂ > 45 mmHg with acidemia, caused by inadequate ventilation.

Pathophysiological Mechanisms of ARF

Mechanism	Definition	Causes	Effect
Ventilation-Perfusion (V/Q) Mismatch	Mismatch between ventilated and perfused lung areas.	Pulmonary embolism, pneumonia, atelectasis.	Hypoxemia.
Diffusion Impairment	Reduced oxygen transfer across the alveolar-capillary membrane.	ARDS, pulmonary fibrosis, interstitial pneumonia.	Hypoxemia despite adequate ventilation.
Hypoventilation	Reduced air movement in and out of the lungs, leading to CO₂ retention.	CNS depression, neuromuscular disorders, obesity.	Hypercapnia and secondary hypoxemia.
Shunting	Blood bypasses ventilated alveoli, preventing oxygenation.	ARDS, pneumonia, large atelectasis.	Severe hypoxemia unresponsive to oxygen therapy.
Increased Work of Breathing	Respiratory muscles overwork to overcome resistance or poor compliance.	COPD exacerbations, asthma, ARDS.	Respiratory fatigue and eventual failure.

Table 1: Pathophysiological Mechanisms of ARF

Ventilation-Perfusion (V/Q) Mismatch

Definition: A mismatch occurs when areas of the lungs are ventilated but not perfused, or perfused but not ventilated.
Causes: Pulmonary embolism (low perfusion), pneumonia, or atelectasis (low ventilation).
Effect: Impairs oxygen delivery and carbon dioxide removal, causing hypoxemia.

Diffusion Impairment

Definition: Thickening or damage to the alveolar-capillary membrane reduces oxygen transfer to the blood.
Causes: Pulmonary fibrosis, ARDS, or severe interstitial pneumonia.
Effect: Decreases arterial oxygenation despite adequate ventilation.

Hypoventilation

Definition: Reduced air movement in and out of the lungs leads to insufficient CO₂ elimination.
Causes: Central nervous system depression (e.g., drug overdose), neuromuscular disorders (e.g., Guillain-Barré syndrome), or severe obesity.
Effect: Causes hypercapnia and secondary hypoxemia.

Shunting

Definition: Blood flows through areas of the lungs without gas exchange, bypassing functional alveoli.
Causes: ARDS, pneumonia, or large atelectasis.
Effect: Results in severe hypoxemia unresponsive to oxygen therapy.

Increased Work of Breathing

Definition: Respiratory muscles work harder to overcome airway resistance or reduced lung compliance.
Causes: COPD exacerbations, asthma, or ARDS.
Effect: Leads to respiratory muscle fatigue and eventual failure.

What are the Main Causes of Acute Respiratory Failure?

Category	Causes	Examples
Pulmonary Causes	Conditions directly impairing lung function.	ARDS, pneumonia, COPD exacerbations, asthma, pulmonary embolism.
Extrapulmonary Causes	Conditions indirectly affecting the respiratory system.	Neuromuscular disorders, CNS depression, thoracic cage abnormalities.
Trauma and External Factors	Physical trauma or external agents affecting ventilation.	Chest trauma, sedative overdose, toxins, or neuromuscular blockers.

Table 2: Main Causes of ARF

Acute respiratory failure (ARF) arises from a wide range of conditions affecting the respiratory system or its control mechanisms. These causes are broadly categorized as pulmonary causes, such as ARDS and pneumonia, directly impair lung function, while extrapulmonary causes, including neuromuscular disorders and CNS depression, indirectly disrupt respiratory mechanics:

Pulmonary Causes

Acute Respiratory Distress Syndrome (ARDS): Severe lung inflammation and alveolar damage leading to profound hypoxemia.
Pneumonia: Infectious consolidation of lung tissue impairs ventilation and gas exchange.
Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: Increased airway obstruction and gas trapping result in hypercapnia.
Asthma: Severe bronchoconstriction impairs airflow, causing hypoxemia and hypercapnia.
Pulmonary Embolism (PE): Blockage of pulmonary arteries disrupts perfusion.

Extrapulmonary Causes

Neuromuscular Disorders: Conditions like Guillain-Barré syndrome or myasthenia gravis weaken respiratory muscles, reducing ventilation.
Central Nervous System Depression: Stroke, trauma, or sedative overdose impairs respiratory drive.
Thoracic Cage Abnormalities: Structural conditions such as kyphoscoliosis limit lung expansion.
Obesity Hypoventilation Syndrome: Excess weight restricts chest wall movement, leading to hypoventilation.

Trauma and External Factors

Chest Trauma: Rib fractures or pneumothorax compromise ventilation mechanics.
Toxins and Medications: Sedatives, opioids, or neuromuscular blockers depress respiratory effort or muscle function.

ARF is a multifaceted condition with diverse etiologies that disrupt normal respiratory physiology (3). Hypoxemia and hypercapnia serve as key markers of dysfunction, emphasizing the importance of understanding the underlying pathology for timely and effective management. Accurate diagnosis and targeted interventions, including mechanical ventilation, are essential to restoring respiratory function and preventing severe complications.

References

Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426. Published 2017 Aug 31. doi:10.1183/13993003.02426-2016
Chen L, Rackley CR. Diagnosis and Epidemiology of Acute Respiratory Failure. Crit Care Clin. 2024;40(2):221-233. doi:10.1016/j.ccc.2023.12.001
Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400(10358):1145-1156. doi:10.1016/S0140-6736(22)01485-4
Villgran VD, Lyons C, Nasrullah A, Clarisse Abalos C, Bihler E, Alhajhusain A. Acute Respiratory Failure. Crit Care Nurs Q. 2022;45(3):233-247. doi:10.1097/CNQ.0000000000000408
Haddad M, Sharma S. Physiology, Lung. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 20, 2023.
Roussos C, Koutsoukou A. Respiratory failure. Eur Respir J Suppl. 2003;47:3s-14s. doi:10.1183/09031936.03.000385037. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27(4):337-349. doi:10.1055/s-2006-948288
Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27(4):337-349. doi:10.1055/s-2006-948288

tidal volume in mechanical ventilation cover photo

The Importance and Measurement of Tidal Volume in Mechanical Ventilation

May 16, 2024

by admin Uncategorized

High-flow oxygen therapy is a modern method of providing oxygen, through nasal cannulas, with a higher volume of heated and humidified air. This special kind of therapy is also known as high-flow nasal cannula (HFNC). It seems to be a promising alternative therapy because it is less complicated and easier.

Modes of Mechanical Ventilation | mechanical ventilation modes

The Most Common Modes of Mechanical Ventilation

May 9, 2024

by admin Uncategorized

Mechanical ventilation is the process of using an external device (machine) to aid gaseous movement in and out of the lung. It serves as a type of life-saving device that facilitates breathing. Also, it’s widely used as an artificial breathing support in surgical cases, extremely ill situations, or when an individual is incapable of breathing on their own. Various modes of mechanical ventilation play a great role in respiratory support, patient stabilization, and provision of pressure to prevent the alveoli from collapsing. Continue reading, as this article provides you with diverse mechanical ventilation modes and some of the most common modes of air circulation.

Pressure Controlled Ventilation (PCV)

Pressure-controlled ventilation is a special kind of assisted respiration whereby a patient’s inspiratory pressure is predetermined. This mechanical ventilation mode provides an amount of aeration that depends on the compliance of the lungs and the resistance of the alveoli. It is an airflow system where the maximum airway force is constant and the total ventilation fluctuates.

PCV is one of the most convincing pressure-limited ventilation (PLV) that is used regularly in the initial stages of newborn care. It is a technique recommended by different centers for preventing lobar emphysema. Although PCV reduces the risk of barotrauma, it could be challenging to provide a sufficient tidal volume (VT) when used in patients with ARDS. Also, an improper setting of this ventilator can lead to hypoxia and respiratory depression.

Volume Controlled Ventilation (VCV)

The modes of mechanical ventilation that involves a preset tidal volume to be provided in a specific amount of time is volume-controlled ventilation. It is usually more simple and comprehensible for most medical practitioners new to assisted air circulation. In this case, total ventilation is always set, the volume of breath supplied is constant, but the inspiratory pressure is unstable.

Most of the time, VCV is commonly used in anesthesia, either in the assisted control (AC) mode or continuous mandatory ventilation (CMV). Due to the increase in peak pressure (PIP) with steady and accurate breathing volume, it usually causes uneven gaseous distribution and volutrauma.

Pressure Support Ventilation (PSV)

A special mode of positive-pressure mechanical ventilation that requires patient initiation of each breath is known as pressure support ventilation. This kind of aided respiration can be administered either through the use of intubation (invasive) or with a mask (non-invasive) ventilatory pattern. It’s known as the most pleasant aided airflow with a useful system that delivers the benefits of the two types of ventilator patterns.

PSV involves setting maximum driving pressure which usually indicates the ventilator flow rate. Sometimes, the patient’s pulmonary compliance, airway resistance, PIP, and breathing efforts frequently affect this flow rate. There is no minimum minute ventilation and the tidal volume provided is influenced by the flow and rate of breathing. Due to a volatile VT, it may also make the lung distend excessively.

Pressure-Limited Time-Cycled Ventilation

Another type of PLV (similar to a pressure-controlled ventilator) that was previously used in neonates is the time-cycled PLV. This mechanical ventilation mode makes use of a predetermined peak pressure and a specified volume of gas within an extended period. While breathing in, this triggered ventilator provides a steady flow of air to the patient.

Previous reports about the use of pressure-limited time-cycled ventilation have shown that lungs are usually susceptible to atelectrauma and barotrauma conditions. In addition, it has been observed that one of the primary factors influencing ventilator-associated lung injury (VALI) is Total ventilation (VT).

Synchronized Intermittent Mandatory Ventilation (SIMV)

This is a unique mode of mechanical ventilation that provides a fixed tidal volume at a predefined frequency. In most cases, synchronized intermittent mandatory air circulation always permits patients to voluntarily breathe on their own. SIMV produces a mandatory breath that is delivered at the same moment the patient starts initiating their breath (spontaneous breath). In addition, positive end-expository pressure (PEEP) can also be administered using this synchronized IMV method.

SIMV is mostly required by people with COPD, neuromuscular disorder, or ARDS and is used alongside pressure support ventilation. In some instances where SIMV is improperly used, there may be an inability to initiate spontaneous breath, fluctuations in intrathoracic force, or severe respiratory failure. This technique of ventilation is risky for hyperventilation, consumes much time, and can cause infection, barotrauma, or cardiac arrhythmias.

High Flow Nasal Cannula (HFNC)

A high-flow nasal cannula is an oxygen therapy commonly called a heated, humidified, high-flow nasal cannula (HHFNC). It entails the delivery of a flexible blend of warmed, humid, and oxygen-rich air at a variable pace that surpasses spontaneous pulmonary flow. Whenever this aeration is used to provide oxygen, the flow is significantly greater than that with conventional nasal cannulas.

In addition, HFNC enhances the functional residual capacity, and accurate distribution of oxygen. This mechanical ventilation mode often has an outcome of improved breathing efficiency due to continuous high oxygen flow that often washes out the anatomical dead space.

Self Adjustable Ventilation (SAV)

Self Adjustable Ventilation is a special ventilator that makes use of detectors to constantly alter the airflow in response to changes in air properties. With the help of this technique, indoor comfort, improved air exchange systems, and environmental sustainability are guaranteed. This often allows great flexibility in ventilator parameters and also blends soothingly with a wide range of conditions.

References

1.https://my.clevelandclinic.org/health/treatments/15368-mechanical-ventilation

2.https://www.sciencedirect.com/topics/medicine-and-dentistry/pressure-controlled-ventilation

3. https://ecampusontario.pressbooks.pub/mechanicalventilators/chapter/volume-control-ventilation/

4.https://ecampusontario.pressbooks.pub/mechanicalventilators/chapter/volume-control-ventilation/

5.https://pubmed.ncbi.nlm.nih.gov/31536312/#:~:text=

6.https://journals.lww.com/jcma/fulltext/2019/10000/volume_targeted_versus_pressure_limited.14.aspx#:~:text=

7. https://www.icliniq.com/articles/respiratory-health/synchronized-intermittent-mandatory-ventilation

8.https://www.uptodate.com/contents/high-flow-nasal-cannula-oxygen-therapy-in-children

Mechanical Ventilation and ICU Ventilators: Learn All Details

December 28, 2023

by admin Uncategorized

Mechanical ventilation and ICU ventilators are critical components in the management of patients with severe respiratory conditions. Understanding their functionality and application is essential for effective patient care. These technologies play an important role in supporting and stabilizing patients in critical conditions.

What is Ventilation?

ICU Ventilation is the process of movement of air from the atmosphere through the airways to the terminal respiratory gas exchange units by the effort of the respiratory muscles or mechanical ICU ventilators if the patient is being ventilated.

What is Respiration?

Oxygen is essential for life. It is required by each human cell for its survival. It is abundantly present in the atmosphere and maintains a remarkably constant concentration of 20.9% in ambient air. Oxygen is taken up by the lungs through the act of inspiration and transported to the cells via the blood.

At the cellular level, oxygen is utilized for the production of energy. In this process, carbon dioxide is released and transported back via the blood to the lungs from where it is expired out into the atmosphere. The act of the exchange of oxygen and carbon dioxide is called respiration.

What is the Difference Between ICU Ventilators and Respirator?

A ventilator is a machine, a system using mechanical power and having several parts, each with a definite function and together performing a particular task. The task here is to provide all or part of the body’s work that is called breathing or ventilation. Respirator is an apparatus that people worn it over their mouth and nose or the entire face to prevent the inhalation of dangerous substances such as: dust, smoke, etc

Indications for Ventilation

Patients who require ventilatory support often develop a common pattern of physiological deterioration, including:

changes in respiratory rate
asynchronous respiratory pattern
changes in mental status and changes in level of consciousness
frequent oxygen desaturation despite increasing oxygen concentration
hypercapnia and respiratory acidosis
circulatory problems, including tachypnea, tachycardia, hypertension, or hypotension.(3)

What is Non-invasive Ventilation (NIV)?

NIV refers to the provision of respiratory support without direct tracheal intubation. As such, it aims to avoid some of the complications inherent with invasive ventilation, such as the need for sedation with risks of hemodynamic instability and subsequent risk of delirium, nosocomial infection, etc.(2)

Recommendations for the use of non-invasive ventilation(4):

COPD exacerbations
Facilitation of weaning/extubation in patients with COPD
Cardiogenic pulmonary edema
Immunosuppressed patients
Do-not-intubate status
End-stage patients as palliative measure
Extubation failure (COPD or congestive heart failure) (prevention)
Community-acquired pneumonia in COPD
Postoperative respiratory failure (prevention and treatment)
Prevention of acute respiratory failure in asthma

Goals of Mechanical Ventilation

One of the most important treads of life support in the emergency department is Mechanical ventilation (MV). It provides time for recovery until the patient’s physiological balance is restored. This is why MV alone is not a unique and specific treatment for a particular disease; however, it has two general and main purposes: to support the injured lung and to protect the healthy lung.

Specific Goals of Mechanical Ventilation

Reversal of Apnea
Reversal of Respiratory Distress
Reversal of Severe Hypoxemia
Reversal of Severe Hypercapnia
Goals of Mechanical Ventilation in Postoperative
Respiratory Failure and Trauma
Goals of Mechanical Ventilation in Shock

One of the specific goals of MV is to promote the optimization of arterial blood gas levels and acid-base balance by providing oxygen and eliminating carbon dioxide (ventilation).(1) For patients with chronic diseases MV can reduce the work of breathing by taking effort from respiratory muscles and maintaining long-term respiratory support.
The ventilator is not a magical therapy that makes patients better but simply a supportive therapy used until more definitive therapies have time to work.

Apnea

Patients with apnea, such as those who have suffered catastrophic central nervous system (CNS) damage, need the immediate institution of mechanical ventilation.(2)

Indications and Contraindications for Non-invasive Ventilation

Recognizing when and when not to use NIV is crucial for its effective application. Below, we have explained the indications and contraindications for non-invasive ventilation for you

Indications (3)

Moderate to severe dyspnoea
Tachypnoea (>25–30 breaths/minute)
Signs of increased work of breathing (abdominal paradox; accessory muscle use)
Fatigue
Acute-on-chronic respiratory failure: pH <7.35; pCO2 >6
Hypoxaemia (use with caution): paO2/FiO2 <27 Kpa

Contraindications (3)

Facial burns/trauma/recent facial upper airway surgery
Vomiting
Upper gastrointestinal surgery
Copious respiratory secretions
Severe hypoxemia
Hemodynamically instability
Severe co-morbidities
Confusion/agitation
Low Glasgow coma score
Unable to protect the airway
Bowel obstruction
Respiratory arrest

NIV today consists almost exclusively of the delivery of positive pressure ventilation via an external interface. There are six broad types of interfaces available;

total face masks (enclose mouth, nose, eyes)
full-face masks (enclose mouth and nose)
nasal mask (covers nose but not mouth)
mouthpieces (placed between lips and held in place by lip seal)
nasal pillows or plugs (inserted into nostrils)
helmet (covers the whole head/all or part of the neck – no contact with face).(3)

What is Invasive Ventilation?

Invasive mechanical ventilation requires access to the trachea, most commonly via an endotracheal tube, and represents the commonest reason for admission to the ICU.(5)ICU Ventilators.

Large multinational surveys confirm the common indications for invasive ventilation to be:

coma 16%
COPD 13%
ARDS 11%
heart failure 11%
pneumonia 11%
sepsis 11%
trauma 11%
postoperative complications 11%
neuromuscular disorders 5%.
NIV contraindications.(5)

Let’s Meet with Biyovent ICU Type Mechanical Ventilator

Biyovent ICU Type Mechanical Ventilator

ICU Ventilator of Biyovent makes a difference in the ventilation process with its unique specifications. Biyovent has been carefully thought out with every detail of the ventilators and developed with a holistic approach. Prepared for mass production in cooperation with Arçelik, Baykar, and Aselsan. ICU Ventilators

What are some specific features of Biyovent?

⦁ Invasive and Non-invasive Ventilation
⦁ Integrated Nebulizer
⦁ High Flow Oxygen Therapy
⦁ Suitable for Pediatric, Adult and Newborn (Optional) Patients
⦁ Smart Ventilation Modes

Learn more details about Biyovent ICU Ventilator

Get in contact with the Biosys Sales Team

References

1- Frank Lodeserto MD, “Simplifying Mechanical Ventilation – Part I: Types of Breaths”, REBEL EM blog, March 8, 2018. Available at: https://rebelem.com/simplifying-mechanical-ventilation-part/.
2- Tobin M.J. 3rd edn. McGraw-Hill Education; 2012. Principles and practice of mechanical ventilation.
3- Popat B, Jones AT. Invasive and non-invasive mechanical ventilation. Medicine (Abingdon). 2012;40(6):298-304. doi:10.1016/j.mpmed.2012.03.010
4- Hess D.R. The evidence for noninvasive positive-pressure ventilation in the care of patients in acute respiratory failure: a systematic review of the literature. Respir Care. 2004;49:810–829.
5- Esteban A., Ferguson N.D., Meade M.O. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008;177:170–177